Advertisement

Die thromboembolische Krankheit

  • Th. Naegeli
  • P. Matis
Conference paper
Part of the Ergebnisse der Chirurgie und Orthopädie book series (ERGEB.CHIRURGIE, volume 38)

Zusammenfassung

Die Thrombose- und Emboliejorschung hat bis in die letzte Zeit durch die Erkenntnisse auf physiologischem, insbesondere gerinnungsphysiologischem Gebiet, aber auch durch die pathologische Anatomie, die innere Medizin und Chirurgie Impulse und Förderungen erfahren. Die Therapie, die noch Mitte der 30er Jahre alles andere als aussichtsreich anmutete und sich in praktisch rein symptomatischen Maßnahmen erschöpfen mußte, ist es heute dank der Forschungsergebnisse der angewandten Gerinnungsphysiologie durchaus geworden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abeshousb, B. S.: Thrombosis and Thrombophlebitis of the renal veins. Urol. a cut. Rev. 49, 661–675 (1945).Google Scholar
  2. Abrahams, D. G.: Intramuscular Heparin. Brit. Med. J. 1950, 1418–1419.Google Scholar
  3. Abrahams and Sh. Howarth: A peripheral action of heparin. Brit. Heart. J. 1950, 429.Google Scholar
  4. Ahlquist, R. P.: Action, of various drugs on arterial blood flow of pregnant canine uterus. J. Amer. Pharm. Assoc. 39, 370–371 (1950).Google Scholar
  5. Alexander, B., A. De Vries, R. Goldstein and G. Landwehr: A Prothrombin conversion accelerator in serum. Science 109, 545 (1949).PubMedGoogle Scholar
  6. Allen, A. W.: Prevention and treatment of thrombosis in deep veins of legs and pulmonary embolism. Chicago M. Soc. Bull. 49, 672–674 (1947).Google Scholar
  7. Allen, and G.A. Donaldson: Venous thrombosis and pulmonary embolism. Bull. New York Acad. Med. 2nd series 24, 619–635 (1948).Google Scholar
  8. Allen, A. W. R. R. Linton and G. A. Donaldson: Thrombosis and embolism: Review of 202 patients treated by femoral vein interruption. Amer. Surg. 118, 728–740 (1943).Google Scholar
  9. Allen, A. W. R. R. Linton and G. A. Donaldson: Venous thrombosis and pulmonary embolism. Bull. New York Acad. Med. 24, 619–635 (1948).Google Scholar
  10. Allen, A. W. R. R. Linton and G. A. Donaldson: Venous thrombosis and pulmonary embolism. Jama 133, 1268–1276 (1947).Google Scholar
  11. Allen, A. W. R. R. Linton and G. A. Donaldson: Venous thrombosis and pulmonary embolism; further experience with thrombectomy and femoral vein interruption. J. Amer. Med. Assoc. 128, 397–403 (1945).Google Scholar
  12. Allen, E.V.: The clinical use of anticoagulants; Report of Treatment with Dicumarol in 1686 postoperative cases: chairman’s Adress. J. Amer. Med. Assoc. 134, 323–329 (1947).Google Scholar
  13. Allen, E.V.: The emergency treatment of vascular occlusions. J. Amer. Med. Assoc. 135, 15–17 (1947).Google Scholar
  14. Allen, E.V.: N. W. Barker and E. A. Hines: Peripheral vascular disease. Saunders & Co., Philadelphia, 1947.Google Scholar
  15. Allen, E.V.: N. W. Barker and J. M. Waugh: A preparation from spoiled sweet clover (3,3’-Methylene-bis-(4-hydroxy coumarin)) which prolongs Coagulation and Prothrombin time of blood: A clinical study. J. Amer. Med. Assoc. 120, 1009–1015 (1942).Google Scholar
  16. Allen, J. G., B. J. Grossmann, R. M. Elghammer, P. V. Moulder, C. L. Mckeen, M. Sanderson, W. Egner and J. M. Crosbie: A protamine titration as an Indication of a clotting defect in certain haemorrhagic states. J. Labor, a. Clin. Med. 34, 473 (1949).Google Scholar
  17. Anning, S. T.: Heredity and leg ulcers. Brit. Med. J. 1950, 1305–1307.Google Scholar
  18. Apitz, K.: Die Bedeutung der Gerinnung und Thrombose für die Blutstillung. Virchows Arch. 308, 540–614 (1942).Google Scholar
  19. Apitz, K.: Über Profibrin. IV Die Agglutination von Blutplättchen durch Profibrin. Z. exper. Med. 105, 89–94 (1939).Google Scholar
  20. Artz, C. P., M. Martin and R. S. Mccleery: Disadvantages of Dicumarol with special reference to therapeutic inadequacies. Amer. J. Surg. 77, 47–52 (1949).PubMedGoogle Scholar
  21. Aschoff, L.: Thrombose und Embolie. Verh. dtsch. Ges. Kreisl.Forsch. VII. Tagung Dresden und Leipzig: Steinkopf 1934.Google Scholar
  22. Askey, J. M., and O. Neurath: IS Digitalis indicated in Myocardial infarction? Jama 128, 1016–1018 (1945).Google Scholar
  23. Atkins, H. S. B.: Postoperative thrombosis. Diskussion on Thrombosis. Proc. roy. Soc. Med. 40, 193–195 (1947).Google Scholar
  24. Aurin, F. B., and L. G. Hermann: Management of venous thrombosis and pulmonary embolism following injuries to extremities. Amer. J. Surg. 76, 586–590 (1948).PubMedGoogle Scholar
  25. Axtrtrup, S.: Hypoprothrombinemia in penicillin treatment of acute Infections of infants. Acta paediatr. 35, 351–354 (1948).Google Scholar
  26. Babioch, G.: Klinische Erfahrungen in der Thrombose-und Emboliebehandlung mit dem Heparinoid Thrombocid. Langenbecks Arch. u. Dtsch. 2. Chir. 263, 497–506 (1950).Google Scholar
  27. De Bakey, M. E., U. A. Ochsner: Phlegmasia cerulea dolens and Gangrene associated with Thrombophlebitis: Case report and review of Literature. Surgery 26, 16–19 (1949).Google Scholar
  28. Bally, P.: Über die klinische Bedeutung des Heparins mit besonderer Berücksichtigung der Heparinbelastung als diagnostisches Mittel. Z. klin. Med. 148, 295–330 (1951).Google Scholar
  29. Barrakling. K. H.: Über klinische Erfahrungen mit dem Antithromboticum Thrombodym Ärztl. Wschr. 6, 699–701 (1951).Google Scholar
  30. Barker, N. W., E. H. Cromer, M. Hurn and J. M. Waugh: The use of dicumarol in the prevention of postoperative Thrombosis and Embolism, with special Reference to Dosage and safe administration Surgery 17, 207–217 (1945).Google Scholar
  31. Barker, N. W., S. Earle Estes and F.D. Mann: Clinical experiences with the anticoagulant, Ethyl Biscoumacetate. Proc. Staff. Met. Mayo Clin. 26, 162–167 (1951).Google Scholar
  32. Barker, N. W., H.H. Hanson and F.D. Mann: Bishydroxy coumarin, Ethyl Biscoumacetate and 4-hydroxy coumarin Anticoagulant No. 63—comperative effects. J. amer. Med. Assoc. 148, 274–277 (1952).Google Scholar
  33. Barker, N. W., K. K. Nygaard, W. Walters U. S. T. Priestley: A statistical study of postoperative venous thrombosis and pulmonary embolism. I, II, III, IV. Proc. Staff Meet Mayo Clin. 15, 769–773 (1940); 16, 1-5, 17-21, 33-37 (1941).Google Scholar
  34. Barnard, R. D.: Adequacy of prothrombin-Synthesis during terramycin-Therapy. New York State J. Med. 51, 1175–1177 (1951).Google Scholar
  35. Barnes, A. C.: Postpartum blood; its clotting mechanism and relationship to the peripheral blood picture. Am. J. Med. Sci. 213, 463–469 (1947).PubMedGoogle Scholar
  36. Barnes, A. R.: The problem of pulmonary embolism. West. J. Surg. 50, 551–556 (1942).Google Scholar
  37. Battle, W. D., R. T. Capps, O. S. Orth and O.O. Meyer: The effects of 4-hydroxycoumarin anticoagulant No. 63 upon the prothrombin time in dogs and human beings. J. Labor. a. Clin. Med. 35, 8–15 (1950).Google Scholar
  38. Bauer, G.: A roentgenological and clinical study of the sequels of thrombosis. Acta chir. Scand. 86 Suppl. 74 (1942).Google Scholar
  39. Bauer, G.: A venographic study of thromboembolic problems. Acta chir. scand. 84, Suppl. 61, 1940.Google Scholar
  40. Bauer, G.: Folgen von postoperativen Venenthrombosen. J. internat. Chir. 11, 213–221 (1951).Google Scholar
  41. Bauer, G.: The Pathophysiology and treatment of the lower leg stasis syndrome. Angiology 1, 1–8 (1950).Google Scholar
  42. Bayer, H., H. Boström, E. Jorpes U. S. Kallner: Intramuscular Administration of Heparin. Acta med. scand. 136, 188–198 (1950).Google Scholar
  43. Bayer, H., H. Boström, Statistik über 500 autoptische Thrombosefälle. Bruns Beitr. 178, 421–426 (1949).Google Scholar
  44. Behrend, M.: Phlebitis, embolism and thrombosis. J. int. Coll. Surg. 9, 552–558 (1946).PubMedGoogle Scholar
  45. Bell, W. N., and E. G. Stuart: Use of desoxycorticosterone acetate in treatment of hyper-heparinemia. Proc. Soc. Exper. Biol. a. Med. 77, 550–551 (1951).Google Scholar
  46. Beller, F. K. jr., u. H. S. Spechter: Untersuchungen des Prothrombinpotentials bei Krebskranken. Z. Krebsforsch. 57, 542–553 (1951).Google Scholar
  47. Belt, T. H.: Thrombosis and pulmonary embolism. Amer. J. Path. 10, 129–144 (1934).PubMedGoogle Scholar
  48. Benichoux: The surgical treatment of massive pulmonary embolism. Report of 22 cases of Trendelenburgs operation. J. internat. Chir. 11, 464–491 (1936).Google Scholar
  49. Bergström, S.: Über Polvsaccharidester-schwefelsäuren mit Heparinwirkung. Z. physiol. Chem. 238, 163 (1936).Google Scholar
  50. Best, C. H., and L. B. Jaques: Heparin in blood clotting and Thrombosis. Ann. New York Acad. Sci. 49, 501–517 (1948).Google Scholar
  51. Beutnagel, J., u. H. C. Friederich: Beeinflussung pathologisch gestörten Haarwachstums durch Vitamin D2 in hohen Dosen. N. Med. Welt, 1950, 779–781.Google Scholar
  52. Birger, J.: The chronic (second) stage of thrombosis in the lower extremities. Its course into ciural ulcer and its treatment. Acta chir. scand. 95, Suppl. 129 (1947).Google Scholar
  53. Bjerkelund, C. J.: A comparison between the effect of intravenously and orally administered dicumarol on the plasma prothrombin levels in man.Google Scholar
  54. Bjerkelund, C. J.: The effect of phenylindanedione on plasma prothrombin and factor V levels and a comparison with the effect of dicumarol. Scand. J. clin. Laborat. Investig. 2, 83–91 (1950).Google Scholar
  55. Blaich U. Tüshaus: Arch. Derm. (D) 188.,683 (1950).Google Scholar
  56. Blau Stein, A. U., J. J. Croce jr., M. Alberian U. N. Richey: Preliminary report on the clinical use of a new anticoagulant, phenylindandione. Circulation 1, 1195–1204 (1950).Google Scholar
  57. Bollmann, J. L., u. F. W. Preston: The effects of experimental administration of dicou-marin. J. Amer. Med. Assoc. 120, 1021–1025 (1942).Google Scholar
  58. Borgström, S. T.: Investigation on the effect of Dicumarol and early ambulation in the prevention of postoperative thromboembolism in a surgical material strongly disposed to thrombosis. Acta Chir. Scand. Suppl. 150 (1950).Google Scholar
  59. Borgström, S. T.: The value of post-operative dicoumarin prophylaxis at „early rising“. Acta Chir. Scand. 95, 47–61 (1947).Google Scholar
  60. Brass, K.: Aufbauund Entstehung der Beinvenenthrombose Frankf. Z. Path. 56, 74–176 (1942)Google Scholar
  61. Brass, K.: u. W. Sandritter: Statistische Untersuchungen an blanden Fernthrombosen, fulminanten und nichttödlichen Lungenembolien am Sektionsgut der Jahre 1905-48. Frankf. Z. Path. 61, 98–115 (1948).Google Scholar
  62. Brass, K.: Über die Zunahme fulminanter Lungenembolien seit der Währungsreform in Frankfurt/M. Ärztl. Forsch. 4, I/662–I/666 (1950).Google Scholar
  63. Breitner, J.: Darf man Anticoagulantien im Wochenbett verwenden? Münch. med. Wschr. 94, 2022–2029 (1952).Google Scholar
  64. Brinkhotjs, K. M.: Clotting defect in haemophilia; deficiencv in plasma factor required for platelet utilization. Proc. Soc. Exper. Biol. a. Med. 66, 117–120 (1947).Google Scholar
  65. Brown, G. E. jr., E.H. Wood and E.H. Lambert: Effects of Tetra-ethy]-ammonium Chlorideon Cardiovascular Reactions in Man to changes in Posture and exposure to Centrifugal Force. J. Applied Physiol. 2, 117–132 (1949).Google Scholar
  66. Bruzelius, S.: Dicumarin in clinical use. Studies on its prophylactic and therapeutic value in the treatment of thromboembolism. Acta chir. scand. (Stockh.) 91, Suppl. 100 (1947).Google Scholar
  67. Buschbeck, H.: Über das Frühaufstehen nach Operationen und im Wochenbett. Dtsch. med. Wschr. 76, 1112–1115 (1951).PubMedGoogle Scholar
  68. Butler, J. J., and D. F. James: Major bleeding resulting from a single dose of dicumarol. Ann. Int. Med. 32, 731–735 (1950).PubMedGoogle Scholar
  69. Butler, S., F.R. Hall and H. N. Sanford: Observations on influence of intravenous histamine and qualitative platelet acticity in coagulation. J. Labor, a. Clin. Med. 36, 710–718 (1950).Google Scholar
  70. Byrne, J. J., and E. E. O’neil: Fatal Pulmonary Emboli. Amer. J. Surg. 83, 47–49 (1952).PubMedGoogle Scholar
  71. Decamp, P. T., A. Ochsner and M. De Bakey: Thromboembolism in children. Ann. Surg. 133, 611–622 (1951).PubMedGoogle Scholar
  72. Decamp, P. T., R. J. Schramel, Ch. J. Ray, N. D. Feibleman, S. A. Ward and A. Ochsner: Ambulatory venous pressure Determination in postphlebitic and related syndromes. Surgery 29, 44–70 (1951).PubMedGoogle Scholar
  73. Carlotti, J., I. B. Hardy, R. R. Linton and P. D. White: Pulmonary Embolism in medical Patients. J. Amer. Med. Assoc. 134, 1447–1452 (1947).Google Scholar
  74. Cathcart, R. T. and D. W. Blood: Effect of Digitalis on the clotting of the blood in normal subjects and in Patients with congestive heart failure. Circulation 1, 1176–1181 (1950).PubMedGoogle Scholar
  75. Chargaff, E.: Studies on chimistry of blood coagulation; protamines and blood clotting. J. Biol. Chem. 125, 671–676 (1938).Google Scholar
  76. Chargaff, E.: u. K. B. Olson: The influence of protamine on the anticoagulant effect in vivo. J. Biol. Chem. 123, 153–167 (1938).Google Scholar
  77. Chernoff, A. J.: Anaphylactic Reaction following Injection of Heparin. New England J. Med. 242, 315–319 (1950).Google Scholar
  78. Clark, W. G.: Effect of rutin on dicoumarolism. Proc. Exper. Biol. a. Med. 69, 97–98 (1948).Google Scholar
  79. Cole, F., and W. P. Kleitsch: Incompatibilitv of lumbar block and anticoagulant therapy. J. Amer. Med. Assoc. 147, 1233–1236 (1951).Google Scholar
  80. Cook, A. W., u. H.A. Lyons: Venous thromboembolic phenomena; their absence in paraplegic and tetraplegic patients. J. Amer. Med. Sci. 218, 155–159 (1949).Google Scholar
  81. Cosgriff, S. W., J. R. Cross and D. V. Habif: The management of venous thrombosis and pulmonary embolism. Surg. Clin. N. Amer. 28, 324–340 (1948).PubMedGoogle Scholar
  82. Cosgriff, S. W., A. F. Diefenbach u. W. Vogt, jr.: Hypercoagulability of the blood associated with Acth and cortisone therapy. Amer. J. Med. 9, 752 (1950).PubMedGoogle Scholar
  83. Crafoord, C, and E. J. Jorpes: Heparin as a prophylactic against thrombosis. J. Amer. Med. Assoc. 116, 2831–2835 (1941).Google Scholar
  84. Van Crefeld, S., and M. M. P. Paulssen: Isolation and properties of the third clotting factor in blood platelets. Lancet 262, 23 (1952).Google Scholar
  85. Cummine, H., and R.N. Lyons: A study in intravascular thrombosis with some new conceptions of the mechanism of coagulation. Brit. J. Surg. 35, 337–363 (1948).PubMedGoogle Scholar
  86. Cyran, W.: Über den Rhythmus des Todes. Die Medizinische 1952, 917–920.Google Scholar
  87. Davidson, C. S., and H. Mac Donald: Effect of vitamin K1-oxide on hypoprothrombinemia induced by dicumarol. New England J. Med. 229, 353–355 (1943).Google Scholar
  88. Davidson, C. S., J. H. Freed and H. Mac Donald: The effect of Vitamin K1-oxide upon the anticoagulant Properties of Dicumarol. Amer. J. Med. Sci. 210, 634–637 (1945).Google Scholar
  89. Davidson, C. S., Dearing, W. H., and F. R. Heilmann: The effect of antibacterial agents on the intestinal flora of Patients: The use of Aureomycin, Chloromycetin, Dihydrostreptomycin, Sulfas-uxidine and Sulfathalidin. Gastroenterology 16, 12–18 (1950).Google Scholar
  90. Davidson, C. S., The effect of Aureomycin on the bacterial flora of the intestinal tract of man: A contribution to preoperative Preparation. Proc. Staff Meet. Mayo Clin. 25, 87–102 (1950).Google Scholar
  91. Davidson, C. S., F. D. Mann and G. M. Medham: The prothrombin and the intestinal bacteria of patients being prepared with Terramycin for surgery of the bowel. Proc. Staff Meet. Mayo Clin. 27, 84–87 (1952).Google Scholar
  92. Davidson, C. S., and G. M. Medham: The effect of Terramycin on the intestinal Bacterial flora of Patients being prepared for intestinal surgery. Proc. Staff Meet. Mayo Clin. 26, 49–52 (1951).Google Scholar
  93. Deutsch, E.: Erfahrungen mit Tromexan, einem neuen Anticoagulans der Dicumarolreihe. Schweiz, med. Wschr. 79, 1010 (1949).Google Scholar
  94. Deutsch, E.: Die Diagnose der Thrombosegefährdung. Klin. Med. 5, 295–304 (1950).Google Scholar
  95. Deutsch, E.: Therapie mit Dicumarolderivaten. Ther. Woche. 3, 77–81 (1952).Google Scholar
  96. Deutsch, E.: u. H. Frischauf: Über die Beeinflussung der Capillarpermeabilität durch Di-(4-oxy-cumarinyl-3)-essigsäure-äthylester. Klin. Med. 6, 385–388 (1951).Google Scholar
  97. Dieckmann, C.: Hirudoid zur Behandlung thrombotischer Prozesse in der Schwangerschaft und im Wochenbett. Med. Klin. 46, 798–799 (1951).PubMedGoogle Scholar
  98. Dietrich, A.: Endothelreaktion und Thrombose. Münch. med. Wschr. 76, 272–274 (1929).Google Scholar
  99. Dietrich, A.: Thrombose, ihre Grundlagen und ihre Bedeutung. Berlin-Wien: Springer 1932.Google Scholar
  100. Ditzel, J.: The effect of Acth on the intravascular erythrocyte aggregation, the sedimentation rate and the plasma fibrinogen content. Nord. Med. 45, 872 (1951).PubMedGoogle Scholar
  101. Dolkart, R. E., B. Halpern, M. Larkin, F. L. Dey and G. De Taeats: The effect of Penicillin upon the clotting activity of blood in normal human subjects. J. Pharmacol, a. Exper. Ther. 96, 291–294 (1949).Google Scholar
  102. Dolkart, R. E., G. De Taeats and B. Halpern: Effect of Penicillin on blood-clotting activity. Proc. Centr. Soc. Clin 19, 71 (1946).Google Scholar
  103. Domanig, E.: Erfahrungsbericht über systematische Thromboseprophylaxe. Wien. Klin. Wschr. 63, 478–80 (1951).PubMedGoogle Scholar
  104. Donner, M.: Strahlungsbedingte Hyperprothrombinaemie und ihre therapeutischen Konsequenzen. Dtsch. med. Wschr. 77, 1326–1328 (1952).PubMedGoogle Scholar
  105. Douglas, A. S., and A. Brown: Effect of vitamin-K Preparations on hyperprothrombinae-mia induced by Dicoumarol and Tromexan. Brit. Med. J. 1952, 412–415.Google Scholar
  106. Ducuing, J. P., A. Guilhem, J. Enjalbert, Poulhes and P. Baux: Le point de départ des phlébites postopératoires. Press. méd. 58, 353–354 (1950).PubMedGoogle Scholar
  107. Duff, J. F., J. W. Linman and R. Bisch: The administration of heparin. Surgery etc. 93, 343–362 (1951).Google Scholar
  108. Duff, J. F.,and W. H. Shull: Fatal hemorrhage in dicumarol poisoning with report of necropsy. J. Amer. Med. Assoc. 139, 762–766 (1949).Google Scholar
  109. Dyckerhoff, H., u. N. GoosSENs: Über die thromboseverhütende Wirkung des Neodyms (Neodympräparat Auer 144). Z. exper. Med. 106, 181–192 (1939).Google Scholar
  110. Vekesparre, W.: Zur Frage der Thromboembolie unter der Berücksichtigung der Häufung und Verhütung auf Grund des Tübinger Krankengutes 1928–1948. Tübingen: 1951.Google Scholar
  111. Eisendorf, L. H.: Phlebothrombosis of lower extremities. Amer. J. Surg. 78, 431–445 (1949).PubMedGoogle Scholar
  112. Elson, L.: Effect of Streptomycin on blood clotting time and prothrombin time in man. Amer. J. Med. Sci. 217, 421–26 (1949).PubMedGoogle Scholar
  113. Esser, A., u. O. Scholl: Erfahrungen mit „Thrombocid“ in der Schwangerschaft, unter der Geburt und in der Laktationsperiode. Med. Welt 20, 319–321 (1951).PubMedGoogle Scholar
  114. Evans, J. A., and R. J. Boller: The subcutaneous use of heparin in anticoagulant Therapy. J. Amer. Med. Assoc. 131, 879–882 (1946).Google Scholar
  115. Evans, J. A.,and J. F. Dee: Anticoagulant treatment of postoperative venous thrombosis and pulmonary embolism. New England J. Med. 238, 1–5 (1948).Google Scholar
  116. Evoy, M. H.: Fatal Pulmonary Embolism. Clinical study of one thousand moven cases collected from the literature including 130 personal cases Northwest. Med. 48, 114–120 (1949).Google Scholar
  117. Eysholdt, K. G.: Gefahren der Thrombocidbehandlung. Die Medizinische 1952, 346–347.Google Scholar
  118. Faxon, H. H., J. H. Flyn and R. M. Anderson: Stellate block as an adjunct to the treatment of pulmonary embolism. New England J. Med. 244, 586–590 (1951).Google Scholar
  119. Fearnley, G. R., u. J. J. Bunim: Effect of Acth on the erythrocyte-sedimentation rate and plasma-fibrinogen and serum protein levels in normal persons. Lancet 261, 1112–1114 (1951).Google Scholar
  120. Feissly, R.: Acta Soc. Helvet. Sci. nat. 2, 212 (1924).Google Scholar
  121. Feissly, R.: Action des surfaces mouillables et non mouillables sur le plasma et les plaquettes sanguines. III. Kongr. Europ. Haematol. Ges. Rom 1951.Google Scholar
  122. Felder, D. A.: Evaluation of the various clinical signs of Thrombophlebitis and experience in the Therapy with anticoagulants. Surgery etc. 88, 337–350 (1949).Google Scholar
  123. Ferguson, J. H.: A review of some basic facts of blood coagulation. Ann. New York Acad. Sci. 49, 486–500 (1948).Google Scholar
  124. Fine, J., and A. Starr: Surgical therapy of thrombosis of deep veins of lower extremities. Surgery 17, 232–239 (1940).Google Scholar
  125. Fischer, A., and T. Astrup: On the administration of Heparin per os. Proc. Soc. Exper. Biol. a. Med. 42, 81–82 (1939).Google Scholar
  126. Fischer, E.: Zur Pathogenese und Therapie der Venenerkrankungen. Med. Welt 1932, 1597–1642.Google Scholar
  127. Fischer, H.: Eine neue Therapie der Phlebitis. Med. Klin. 1910, 1172–1173.Google Scholar
  128. Fisher, M. M., L. A. Hochberg and N. D. Wilensky: Recurrent Thrombophlebitis in obscure malignant Tumor of the Report of 4 cases. J. Amer. Med. Assoc. 147, 1213–1216 (1951).Google Scholar
  129. Fleming, A., and E. W. Fish: Influence of Penicillin on Coagulation of Blood, with Especial reference to certain Dental operation. Brit. Med. J. 1947, 242–243.Google Scholar
  130. Foley, W. T., and J. S. Wright: Long term anticoagulant therapy for cardiovascular diseases Amer. J.Med. Sci. 217, 136–142 (1949).Google Scholar
  131. Fonio, A.: Über das funktionelle Verhalten der Thrombocyten beim Gerinnungsvorgang. Die Medizinische 1952, 1–4.Google Scholar
  132. Fonio, AÜber die retraktionsauslösende Funktion der Thrombocyten. Schweiz. Med. Wschr. 78, 973–974 (1948).PubMedGoogle Scholar
  133. Fonio, A Weitere Forschungsergebnisse über die Funktion der isolierten Strukturelemente der Thrombocyten. III. Kongr. Haematolog. Ges. Rom 1951.Google Scholar
  134. Fontaine, R.: Identification et traitement des embolies pulmonaires, l’embolectomie pulmonaire exceptée. J. Chir. 62, 249–266 (1946).Google Scholar
  135. Freeman, N. E., u. R. S. Gilfillan: Regional Heparinization after thromboend arterectomy in the traetment of obliterative Arterial Disease Surgery 31, 115–131 (1952).Google Scholar
  136. Freeman, E. J. Wylie and R. S. Gilfillan: Regional heparinization in vascular surgery. Surgery etc. 90, 406–12 (1950).Google Scholar
  137. Frericks, C. T., J. G. Tillotson and J. M. Hayman jr.: Effect of rutin on capillary fragility and permeability. J. Labor. a. Clin. Med. 35, 933–939 (1950).Google Scholar
  138. Frey, S.: Die Embolie. Leipzig: Thieme 1935.Google Scholar
  139. Friedrich, H. W.: Experimenteller Beitrag zur Thrombocidbehandlung der Thrombose. Ärztl. Wschr. 5, 178–181 (1950).Google Scholar
  140. Friedrich, H. W.: Experimentelle Untersuchungen über Fibrinolyse durch Thrombocid. Ärztl. Wschr. 6, 352–354 (1951).Google Scholar
  141. Friedrich, H. W.: u. Th. Hockerts: Tierexperimentelle Untersuchungen über die auch therapeutisch erzielte Durchblutungsbesserung bei Thrombosen. Ärztl. Wschr. 7, 814–818 (1952).Google Scholar
  142. Friman-dahl, J.: Roentgen Examination in mesenteric thrombosis. Amer. J. Roentgenol. 64, 610–616 (1950).Google Scholar
  143. Fritzsche, R., u. Th. Reich: Die mathematische Beurteilung einer Statistik über Sofort-und Frühaufstehen nach Operationen als Thromboseprophylaxe. Schweiz. med. Wschr. 81, 469–473 (1951).PubMedGoogle Scholar
  144. Frykholm, R.: Pathogenesis and mechanical prophylaxis of venous thrombosis. Surgery etc. 71, 306–312 (1940).Google Scholar
  145. Fuller, B. F., and N. W. Barker: The effect of Vitamin K 1 administered orally on the control of the coagulation defect induced by dicumarol. Minnesota Med. 34, 326–329 (1951).PubMedGoogle Scholar
  146. Galt, J., and R. B. Hunter: The Effect of Aureomycin on certain liver function tests and blood coagulation. Amer. J. Med. Sci. 220, 508–510 (1950).PubMedGoogle Scholar
  147. Geissendörfer, R.: Thrombose und Embolie. Leipzig: Barth 1935.Google Scholar
  148. Gervais, M.: La médication anticoagulante. L’union Med. Canada 80, 1301–1306 (1951).Google Scholar
  149. Gilbert, N. C., and L. A. Nalefski: The effect of heparin and dicumarol in increasing the coronary flow volume. J. Labor. a. Clin. Med. 34, 797–805 (1949).Google Scholar
  150. Gilbert, N. C., R. A. Trump and G. De Takats: Effect of Digitalis on the clotting mechanism. Jama 124, 736 (1944).Google Scholar
  151. Goodwin, J. F., and A. G. Mcgregor: Anticoagulant therapy with heparin in Pitkin’s menstruum. Lancet 254, 667–671 (1950).Google Scholar
  152. Griffith, J. Q. jr., J. F. Couch and M. A. Lindauer: Effect of rutin on increased Capillary fragility in man. Amer. Heart. J. 28, 758–762 (1944).Google Scholar
  153. Gripe, R. P.: Severe hemorrhage due to Tromexan. New. England J. Med. 245, 803–807 (1951).Google Scholar
  154. Gross, R.: Über den Wert von Bluttransfusionen bei thrombopenischer Blutungsbereitschaft. Dtsch. med. Wschr. 76, 1565–1568 (1951).PubMedGoogle Scholar
  155. Grüning, W.: Klinische Erfahrungen mit dem Heparinoid „Thrombostop“. Med. Mschr. 5, 281–283 (1951).PubMedGoogle Scholar
  156. Guéguen, J., et J. P. Soulier: Action de la phényl-indanedione sur le taux de la prothrombine II. Utilisation de la P. I. D. en clinique humaine. Rev. d’hématol. 3, 185–195 (1948).Google Scholar
  157. Gutteridge, N. M.: The heparin protamine Test and its clinical significance. Med. J. Austral. 38, 403–408 (1951).Google Scholar
  158. Hagen, P.: The effect of hyaluronidase on the absorption of heparin. Med. J. Austral. 39, 471–473 (1952).Google Scholar
  159. Haley, T. J., u. F. Stolarsky: Effect of histamine and antihistaminics on coagulation of normal and heparinized rabbit plasma. Proc. Soc. Exper. Biol. a. Med. 76, 299–301 (1951).Google Scholar
  160. Haley, T. J., Effect of Thiazine, oxazine and phenazine dyes on normal and heparinized rabbit plasma. Proc. Soc. Exper. Biol. a. Med. 73, 103–107 (1950).Google Scholar
  161. Halpern, B. N., L. Guillaumat et S. Cruchaud: Action de l’histamine et des anti-hista-miniques de synthese sur la permeabilite capillaire de la barriere hemato-oculaire. Acta allerg. 1, 376–381 (1948).Google Scholar
  162. Halse, Th.: Das postthrombotische Kreislaufsyndrom und seine operative Behandlung. Langenbecks Arch. u. Dtsch. Z. Chir. 270, 30–35 (1951).Google Scholar
  163. Halse, Th.: Fibrinolyse. Eine experimentelle und klinische Studie zur 4. Phase der Blutgerinnung. Freiburg: Editio Cantor 1948.Google Scholar
  164. Halse, Th.: Fortschritte bei der Behandlung der akuten Thrombose, Thrombophlebitis und Embolie mit Heparin, Dicumarol und Thrombocid. Dtsch. med. Wschr. 74, 1326–1330 (1949).Google Scholar
  165. Halse, Th.: Gerinnungsferment, fibrinolytisches Ferment. Dtsch. med. Wschr. 72, 81–83 (1947).PubMedGoogle Scholar
  166. Halse, Th.: Grundsätzliche Betrachtungen über den Prothrombintest und seine Leistungsfähigkeit in der klinischen Praxis. Ärztl. Wschr. 1950, 384–390.Google Scholar
  167. Halse, Th.: Heparin und Heparinoide, Dicumarol. Stuttgart: Hirzel 1950.Google Scholar
  168. Halse, Th.: Kontrolle der Dicumarolmedikation an Hand der Prothrombinzeit und über die Möglichkeit, dieselbe durch einen einfachen Gerinnungstest (Mikromethode) zu ersetzen. Dtsch. med. Wschr. 76, 522–525 (1951).Google Scholar
  169. Halse, Th.: Phlebographische Funktionsdiagnostik bei venöser Insuffizienz der unteren Extremitäten. Z. Kreislaufforsch. 41, 481–491 (1952).PubMedGoogle Scholar
  170. Halse, Th.:Postthrombotische Störungen nach konservativer und spezifischer Behandlung tiefer Bein-venenthrombosen. Med. Mschr. 4, 422–423 (1949).Google Scholar
  171. Halse, Th.: Thrombostase und Thrombolyse mit Heparin und Heparinoiden. Langenbecks Arch. u. Dtsch. Z. Chir. 264, 84–91 (1950).Google Scholar
  172. Halse, Th.: Tromexan — ein echter oder scheinbarer Fortschritt ? Dtsch. med. Wschr. 77, 1634–1636 (1952).Google Scholar
  173. Halse, Th.: Über die vegetative Regulation der Fibrinolyse. Schweiz, med. Wschr. 77, 411–113 (1947).Google Scholar
  174. Halse, Th.: u. J. Bünger: Bemerkungen zur Thromboembolie-Prophylaxe mit Bewegungsübungen, Massage und Frühaufstehen. Chirurg 21, 479–480 (1950).PubMedGoogle Scholar
  175. Halse, Th.: u. G. Caroli: Weitere Beobachtungen über Beeinflussung des Defibrinierungsvermögens im Blute unter atmosphärischen Einflüssen. Ärztl. Forsch. 5, 1/147–1/152 (1951).Google Scholar
  176. Halse, Th.: u. H. Lossnitzer: Untersuchungen über den Einfluß der Witterung auf das fibrinolytische Potential als Beitrag zur Frage einer Meteorotropie der Thrombosegefährdung. Dtsch. med. Wschr. 74, 790–793 (1949).Google Scholar
  177. Halse, Th.: u. G. Quennet: Zur Frage der klimatischen Einflüsse in der Thrombogenese. Bruns’ Beitr. 177, 287–300 (1948).Google Scholar
  178. Halse, Th., u. M. Schmitz: Thrombostatische und thrombolytische Wirkung eines synthetischen Heparinpräparates. — Experimentelle und klinische Erfahrungen mit dem Heparinoid Thrombocid. Med. Klin. 44, 857–861 (1949).Google Scholar
  179. Hanson, H. H., N. W. Barker and F. D. Mann: Clinical experiences with 4-hydroxycoumarin anticoagulant No. 63 and the antagonistic Effect of menadione and Vitamin K 1. Circulation 4, 844–853 (1951).PubMedGoogle Scholar
  180. Hardy, H., H. Henckel u. K. Schreier: Blutgerinnung und Aminosäuren. Studien in vitro. Z. exper. Med. 116, 412–422 (1950).Google Scholar
  181. Hartenbach, W.: Die Einwirkung von Dicumarol auf die Leberfunktion und auf das Capillar-system. Dtsch. med. Wschr. 76, 340–342 (1951).PubMedGoogle Scholar
  182. Hartenbach, W.: Die therapeutische Wirksamkeit von Dicumarol-Suppositorien. Dtsch. med. Wschr. 76, 1455–1456 (1951).PubMedGoogle Scholar
  183. Hartert, H.: Die Thrombelastographie. Eine Methode zur physikalischen Analyse des Blutgerinnungsvorganges. Z. exper. Med. 117, 189–203 (1951).Google Scholar
  184. Hartenbach, W.: Thrombelastographische Untersuchungen zur Fibrinolyse. Klin. Wschr. 28, 77 (1950).Google Scholar
  185. Hartenbach, W.:Thrombelastographische Untersuchungen zur Retraktion. Klin. Wschr. 28, 78–79 (1950).Google Scholar
  186. Hartenbach, W.: u. E. Walch: Gibt es eine percutané Thromboembolieprophylaxe? Dtsch. med. Wschr. 76, 1535–1537 (1951).Google Scholar
  187. Hauch, E. W., and N. W. Barker: Experiences with heparin: Comparative Effects of intravenous and subcutaneous administration in the same individuals. J. Labor. a. Clin. Med. 38, 550–554 (1951).Google Scholar
  188. Hauch, E. W., H. M. Carryer and Don. R. Mathieson: Hypersensitivity to Heparin-Report of 3 cases. Staff Meet. Mayo Clin. 27, 163–166 (1952).Google Scholar
  189. Hausner, E. P., C. L. Schafer, M. Corson, O. Johnson, Th. Turjillo and Langham, Wright: Clinical evaluation of Dicumarinyl Derivatives with a metabolic study of the radioactively labeled anticoagulants in animals. Circulation 3, 171–181 (1951).PubMedGoogle Scholar
  190. Hellerstein, H. K., and J. W. Martin: Incidence of thromboembolic lesions accompanying myocardial infarction. Amer. Heart. J. 33, 443–452 (1947).PubMedGoogle Scholar
  191. Hellsten, H.: Phlebographic studies and heparin treatment in thromboembolic diseases. Acta chir. scand. 86 Suppl. 73 (1942).Google Scholar
  192. Henftling, Th., u. J. Scheele: Problem der perkutanen Thrombosebehandlung. Die Medizinische 1952, 1632–1633.Google Scholar
  193. Herfort, R. A., and S. Standard: Oral streptomycin in Surgery of the large bowel: The production of secondary hypoprothrombinemia. Ann. Surg. 128, 987–992 (1948).Google Scholar
  194. Heusser, H.: Postoperative Blutveränderungen und ihre Bedeutung für die Entstehung der Thrombose. Dtsch. Z. Chir. 210, 132–183 (1928).Google Scholar
  195. Hiller, E.: Experimentelle Untersuchungen über den Einfluß des Flavonolabkömmlings Rutin auf den anaphylaktischen Schock. Z. exper. Med. 115, 638–650 (1950).Google Scholar
  196. Hiller, E.: u. O. Rollwagen: Untersuchungen unter dem Einfluß oraler Gaben von Glykokoll Ascorbinsäure-Calcium auf die Blutgerinnungszeit. Klin. Wschr. 27, 503–505 (1949).Google Scholar
  197. Hines, E. A., and N. W. Barker: Anticoagulant therapy in chronic cardiovascular disease. Med. Clin. N. Amer. 33, 335–345 (1949).PubMedGoogle Scholar
  198. Hines, L. E., and D. L. Kessler: Effect of Penicillin on Heparin tolerance. Jama 128, 794–796 (1945).Google Scholar
  199. Hirschboeck, J. S.: The effect of operation and illness on clot retraction: Description of a new method. J. Labor. a. Clin. Med. 33, 347–355 (1948).Google Scholar
  200. Hirschboeck, J. S.: and M. Woo: A clinical evaluation of the blood „sludge“ Phenomenon. Amer. J. Med. Sci. 219, 538–541 (1950).PubMedGoogle Scholar
  201. Hoejensgaard, J. C.,and M. Schwartz: Heparin hypersensitivity. Acta allergol. (Kopenh.) 2, 7–13 (1949).Google Scholar
  202. Hogben, C. A. M., and E. V. Allen: The relationship between Prothrombin Time and bleeding in the clinical use of Dicumarol after Operation. Circulation 2, 369–372 (1950).PubMedGoogle Scholar
  203. Homans, J.: Late results of femoral thrombophlebitis and their treatment. New England J. Med. 235, 249–253 (1946).Google Scholar
  204. Homans, J.: The Management of recovery from venous thrombosis in the lower limbs. Surgery 26, 8–15 (1949).PubMedGoogle Scholar
  205. Honorato, C. R.: Plasmatic cofactor of Thromboplastin; its adsorption with prothrombin and fibrinogen by alumina and tricalcium phosphate gels. Amer. J. Physiol. 150, 381–388 (1947).PubMedGoogle Scholar
  206. Honorato, R., y C. Gomez: Thrombosis experimental y su relacion con los digitalicos. Rev. Soc. argent. Biol. 24, 295–300 (1948).PubMedGoogle Scholar
  207. Honorato, R., u. M. Lopetegui: Relacion de los digitalicos con la coagulacion sanguinea; su antagonismo con el dicumarol. Rev. Soc. argent. Bio]. 24, 286–294 (1948).Google Scholar
  208. Horan, F. E., F. G. Hirsch, L. A. Wood and J. S. Wright: Surface effects on blood clotting components as determined by zeta-potentials. J. Clin. Invest. 24, 202–211 (1950).Google Scholar
  209. Hueck, O.: Histologische Untersuchungen an Versuchstieren über die Wirkung hoher Dicumarol-und Tromexandosen auf die Leber und andere Organe. Arch. exper. Path. u. Phar-mokol. 212, 302–310 (1950).Google Scholar
  210. Hunter, W. C, J. J. Krygier, J. C. Kennedy and V. D. Sneeden: Etiology and Revention of thrombosis of the deep leg veins: A study of 400 cases. Surgery 17, 178–190 (1945).Google Scholar
  211. Hunter, W. C., V. D. Sneeden, Th. D. Robertson and G. A. C. Snyder: Thrombosis of the deep. Veins of the leg, its clinical significance as exemplified in 351 autopsies. Arch. Int. Med. 68 1–17 (1941).Google Scholar
  212. Innerfield, I., A. Angrist, J. W. Benjamin and L. A. Kanegis: Effect of aureomycin upon blood coagulation time, ac-globulin and prothrombin activity. Amer. J. Physiol. 166, 578–583 (1951).PubMedGoogle Scholar
  213. Irish, U. D., and L. B. Jaques: The effect of Dicumarol upon Plasma fibrinogen. Amer. J. Physiol. 143, 101–104 (1945).Google Scholar
  214. Jacox, R. R.: Studies on the activation of a serum „prothrombin conveiting factor“ J. Clin. Invest. 28, 492–504 (1949).Google Scholar
  215. Jaeger, A.: Strömungstechnisches zur Venenthrombose. Z. exper. Med. 100, 502–511 (1937).Google Scholar
  216. James, D. F., J. L. Bennet, P. Scheinberg and J. J. Butler: Clinical studies on dicumarol hypoprothrombinemia and vitamin K-preparations, superiority of vitamin K 1 oxide over menadione sodium bisulfite, Vsp and synkayvite in reversing dicumarol hypo-prothrombinemia. Arch. Int. Med. 83, 632–652 (1949).Google Scholar
  217. Jaques, L. B., E. Gordon and E. Lepp: A new prothrombopenic drug, phenylindanedione. Canad. Med. Assoc. J. 62, 465–470 (1950).PubMedGoogle Scholar
  218. Jaschke, Th.: Die zentrale Bedeutung des Kreislaufs für die Prophylaxe der postoperativen Thrombose und Embolic Ärztl. Forsch. 3, 41 (1949).Google Scholar
  219. Johow, R.: Die Bekämpfung der Capillarschäden und der dadurch bedingten Blutungen bei der Behandlung der Thrombose mit Dicumarinen. Med. Klin. 44, 1288–1291 (1949).Google Scholar
  220. Johow, R.: u. H. A. Thiess: Über Dicumarinintoxikation. Med. Klin. 45, 1161–1165 (1950).Google Scholar
  221. Jordan, R. A., R. D. Miller, J. E. Edwards and R. L. Parker: Thromboembolism in acute and in healed myocardial infarction. — I. Intracardiac mural thrombosis. Circulation 6, 1–6 (1952).PubMedGoogle Scholar
  222. Jorpes, J. E.: Die Behandlung der Thrombose mit gerinnungshemmenden Mitteln. Erg. in. Med. Neue Folge 2. Bd. (1951).Google Scholar
  223. Jorpes, J. E.: Die Bekämpfung der Thrombose durch Anticoagulantia, Heparin und Dicumarin. Bull. Schweiz. Akad. Med. Wiss. 3, 320–332 (1948).PubMedGoogle Scholar
  224. Jorpes, J. E.: Die spezifische Thrombosebehandlung, ein Beitrag der Chemie zur Medizin. Schweiz. med. Wschr. 77, 167–177 (1947).Google Scholar
  225. Jorpes, J. E.: Heparin in the treatment of thrombosis 2nd Ed. London Oxford piess. 1946.Google Scholar
  226. Jorpes, J. E.: On the Dosage of the Anticoagulants, Heparin and Dicumarol, in the treatment of Throm-bocid. Forther Comments on the Results obtained in Some Swedish Clinics. Acta chir. scand. (Stockh.) Suppl. 149 (1950).Google Scholar
  227. Jorpes, J. E.: The origin and the physiology of Heparin: The specific therapy in thrombosis. Ann. Int. Med. 27, 361–370 (1947).PubMedGoogle Scholar
  228. Jorpes, J. E.: Über die Wirkungsweise des Heparins. Scand. Arch. Physiol 80, 202 (1938).Google Scholar
  229. Jorpes, J. E.: H. Boström and V. Mutt: The Linkage of the Amino group in Heparin. J. Biol. Chem. 183, 607–615 (1950).Google Scholar
  230. Jorpes, J. E.: P. Ednan and T. Thaning: Neutralization of action of heparin by protamine. Lancet 2, 975–976 (1934).Google Scholar
  231. Jorpes, J. E.: H. Holmgren u. O. Wilander: Über das Vorkommen von Heparin in den Gefäßwände und in den Augen. Z. mikr.anat. Forsch. 42, 279 (1937).Google Scholar
  232. Jorpes, J. E.: J. Kallner u. H. Boström: Protamine for intravenous use in man und in animal experiments. Acta med. scand. (Stockh.) 134, 444–447 (1949).Google Scholar
  233. Jürgens, R.: Die Wirkung von Vitamin K 1 auf die Dicumarolhypoprothrombinämie und die Accelerationsfaktoren. VI. Kongr. Europ. int. Haematologen-Ges. Rom 1951.Google Scholar
  234. Jürgens, R.: Normale und pathologische Blutstillungsregulationen. Schweiz. med. Wschr. 74, 113 (1944).Google Scholar
  235. Jürgens, R.: Experimentelles und Klinisches zur Pathogenese der hämorrhagischen Diathesen. Dtsch. med. Wschr. 75, 1727–1728 (1950).PubMedGoogle Scholar
  236. Jürgens, R.: Über Beeinflussung der experimentellen Hypoprothombinämie durch Vitamine. Z. Vitaminforsch. (Schwz.) 19, 342–361 (1948).Google Scholar
  237. Jürgens, R.: u. H. Braunsteiner: Zur Pathogenese der Thrombose. Schweiz. med. Wschr. 80, 1388 (1950).PubMedGoogle Scholar
  238. Jürgens, R.: u. A. Studer: Zur Wirkung des Thrombins. Helvet. physiol. Acta 6, 130–149 (1948).Google Scholar
  239. Jürgens, R.: Beeinflussung der Bildung des Prothrombins im Tierversuch. Schweiz. med. Wschr. 82, 1119 (1952).PubMedGoogle Scholar
  240. Kabat, H., E. F. Stohlman and M. J. Smith: Hypoprothrombinemia induced by administration of indandione derivatives. J. Pharmacol. a. Exper. Ther. 80, 160–170 (1944).Google Scholar
  241. Kaindl, F., J. Schmid u. B. Thurnher: Venendruck und Phlebographie bei venösen Thrombosen. Med. Klin. 45, 1436–1438 (1950).PubMedGoogle Scholar
  242. Katz, R., u. H. Ducci: Un nuevo anticoagulante fenilindandiona. Rev. méd. Chile 80, 104–109 (1952).PubMedGoogle Scholar
  243. Kaulla, K. N. V.: Über Hyperprothrombinämie Klin. Wschr. 22, 646 (1943).Google Scholar
  244. Kaulla, K. N. V.: Klinische Fortschritte auf dem Gebiete der Blutgerinnung unter besonderer Berücksichtigung neuerer Anticoagulantien, der lokalen Haemostatica und der Fibrinolyse. Berlin-München: Urban & Schwarzenberg 1949.Google Scholar
  245. Kaulla, K. N. V.: u. E. Husemann unter Mitarbeit v. R. Kapesser: Beitrag zur Synthese heparinähnlicher Körper. Z. exper. Med. 114, 722–732 (1945).Google Scholar
  246. Kaulla, K. N. V.: u. R. Pulver: Tierexperimentelle Untersuchungen mit dem neuen Antithromboticum Tromexan. Schweiz. med. Wschr. 78, 806–810 (1948).Google Scholar
  247. Kautzsch, E.: Bemerkungen zur gerinnungshemmenden Wirkung und Anwendung der Hi-rudoidsalbe. Dtsch. med. Wschr. 75, 1529–1532 (1950).PubMedGoogle Scholar
  248. Kay, J. H., G. Balla, S. B. Hutton jr. and A. Ochsner: The prophylaxis of intravascular clotting by the use of alphatocopherol and calcium. New Orleans Med. a. Surg. J. 103, 116–120 (1950).Google Scholar
  249. Kay, J. H. and S. Mutton: Studies on an antithrombin I. The antithrombic activity of alpha tocopherol phosphate. Bull. Tulane Medical Faculty 9, 122–126 (1950).Google Scholar
  250. Kay, J. H. S. B. Hutton jr., G.N. Weiss and A. Ochsneb: Studies on an Antithrombin III: A Plasma-Antithrombin-test for the prediction of intravascular clotting. Surgery 28, 24–28 (1950).PubMedGoogle Scholar
  251. Kay, J. H. S. B. Hutton jr. and G. N. Weiss: Studies on an antithrombin II: Identification of an antithrombin in plasma: Composition of fibrinogen B. Bull. Tullane Medical Faculty 9, 127–132 (1950).Google Scholar
  252. Kibby, Ch. K.: The thrombo-embolism problem. Amer. J. Med. Sci. 215, 220–225 (1948).Google Scholar
  253. Kibby, Ch. K.: Venous thrombosis and pulmonary embolism. Surg. Clin. N. Amer. 26, 1389–1403 (1946).Google Scholar
  254. Kibby, Ch. K.: and W. T. Fitts jr.: Thromboembolic complications in surgical Patients. Surgery 27, 564–571 (1950).Google Scholar
  255. Kneppeb, R.: 1st die Thromboembolic überwunden? Med. Welt 1951, 1404–1406.Google Scholar
  256. Knisely, M. H.: Blood clotting and other factors. Transactions of the Fourth Conference on Blood clotting and Allied Problems. Josiah Macy, Jr. Foundation 1951.Google Scholar
  257. Knisely, M. H.: E. H. Bloch, T. S. Eliot and L. Wabner: Sludged blood. Trans. Amer. Ther. Soc. 48-49, 95–112 (1950).Google Scholar
  258. Koller, F.: Anticoagulantien-Therapie. III. Kongr. europ. Haematologen-Ges. Rom 1951.Google Scholar
  259. Koller, F.: Die Prophylaxe und Therapie der Thrombose mit Anticoagulantien. Helvet. med. Acta, Ser. A 16, 184–217 (1949).Google Scholar
  260. Koller, F.: Progrés récents dans le traitement de la thromboembolie par les anticoagulants. Méd. et Hyg. 10, 339–341 (1952).Google Scholar
  261. Koller, F.: u. E. Held: Der Prothrombin-und Faktor VII-Gehalt des Blutes am Ende der Schwangerschaft und beim Neugeborenen. Gynaecologia 134, 43–46 (1952).PubMedGoogle Scholar
  262. Koller, F.: A. Loeliger u. P. Flückiger: Fortschritte in der Handhabung der Dicumaroltherapie. Vereinfachung der Kontrolle, Vitamin K 1 als Antidot. Helvet. med. Acta Series A 19, 411–416 (1952).Google Scholar
  263. Koller, F.: F. Duckebt U. H. Hu-Wang: Über einen,neuen Gerinnungsfaktor (Faktor VII) und seine klinische Bedeutung. Dtsch. med. Wschr. 77, 528–533 (1952).PubMedGoogle Scholar
  264. Koncz, J., u. E. Bücherl: Beitrag zur Wirkungsweise des Anticoagulans Thrombocid. Klin. Wschr. 29, 650 (1951).PubMedGoogle Scholar
  265. Kraus, A. P., S. Peblow and K. Singer: Danger of Dicumarol treatment in pregnancy. J. Amer. Med. Assoc. 139, 758–762 (1949).Google Scholar
  266. Kratjse, G. R.: Roentgendiagnosis of pulmonary infarcts. Radiology 45, 107–119 (1945).Google Scholar
  267. Krieg, E.: Die Behandlung von Beinthrombosen in der Praxis. Praxis 39, 351–354 (1950).PubMedGoogle Scholar
  268. Kühnau, J.: Rutin, ein neuer wasserlöslicher Wirkstoff von Vitamincharakter. Klin. Wschr. 27, 294–297 (1949).Google Scholar
  269. Kuschinsky, G., u. H. Ludewig: Permeabilitätsänderungen durch Dicumarol unabhängig von Änderungen der Prothrombinzeit. Arch. exper. Path. (D.) 210, 404–408 (1950).Google Scholar
  270. Lange, K.: Die Behandlung der Lungenembolie mittels örtlicher Betäubung. Schweiz. med. Wschr. 76, 65–67 (1946).Google Scholar
  271. Lasseb, R. P., M. Versakos and L. Loewe: The influence of aureomycin on human coagulability. Angiology 1, 233–235 (1950).Google Scholar
  272. Läwen, A.: Über Indikationsstellung, Technik und Erfolge der operativen Behandlung der blanden Venenthrombose. Zbl. Chir. 65, 1089–1094 (1938).Google Scholar
  273. Lee, C. C., L. W. Trevoy, J. W. T. Sfinks and L. B. Jaques: Dicumarol labelled with C14. Proc. Soe. Exp. Biol. a. Med. 74, 151 (1950).Google Scholar
  274. Leger, L., et L. Quénu: Les thromboses veineuses du système porte. Presse méd. 60, 1031–1035 (1952).PubMedGoogle Scholar
  275. Leissner, H.: Use of heparin in obstetric practice as means of preventing thrombosis. Acta med. scand. 107, 127–130 (1941).Google Scholar
  276. Leithauser, D. J.: Early ambulation and related procedures in surgical management. Springfield, Ill.: Charles C. Thomas 1946.Google Scholar
  277. Leithauser, D. J.: and H. L. Bergo: Early rising and ambulatory activity after operations. Means of preventing complications. Arch. Surg. 42, 1086–1093 (1941).Google Scholar
  278. Leithauser, D. J.: L. Saraf, St. Smyka and M. Sheridan: Prevention of embolic complications from venous thrombosis after surgery standardized Regimen of early ambulation. Jama 147, 300–303 (1951).Google Scholar
  279. Lenggenhager, K.: Die toxische Lungenembolie. Schweiz. med. Wschr. 80, 297–300 (1950).Google Scholar
  280. Lenggenhager, K.: Über die Entstehung, Erkennung und Vermeidung der postoperativen Fernthrombose. Stuttgart: Thieme 1948.Google Scholar
  281. Lebiche, R.: Considération sur le traitement chirurgical de la phlébite du membre inférieur et de ses séquelles éloignés. J. internat. Chir. 3, 585 (1938).Google Scholar
  282. Lenggenhager, K.: Les embolies de l’artère pulmonaire et des artères des membres. Masson édit. Paris (1947).Google Scholar
  283. Lenggenhager, K.: Physiologie pathologique de la thrombose veineuse du membre inférieur. Presse méd. 58, 1121–1122 (1950).Google Scholar
  284. Leriche, R.: Resultats éloignés du traitement des séquelles phlebitiques du membre inférieur. Mém. Acad. Chir. 75, 397–402 (1949).Google Scholar
  285. Leriche, R.: Traitement chirurgical des suites éloignées des phlebites et des grands oedèmes non médicaux des membres inférieures. Bull. Soc. nat. Chir. 53, 187 (1927).Google Scholar
  286. Leriche, R.: Traitement des séquelles postphlebitiques. Progr. méd. Paris 77, 243–251 (1949).PubMedGoogle Scholar
  287. Levin, W. C, and A. Ruskin: Studies on the effects of digitoxin on the coagulation mechanism Amer. J. Med. 7, 133 (1949).Google Scholar
  288. Lewitus, Z. A.: Prothrombinopenic effect of Penicillin. Harefua 35, 15 (1948).Google Scholar
  289. Lezius, A.: Der Lungenabsceß. Erg. Chir. 29, 511–582 (1936).Google Scholar
  290. Lilly, G. D., and R. M. Lee: Complication of anticoagulant Therapy. Surgery 26, 957–969 (1949).PubMedGoogle Scholar
  291. Linman, J. W., J. F. Duff and S. Serfontain: Anticoagulant therapy with depository heparin. Amer. Mich. Med. Bull. 16, 69–73 (1950).Google Scholar
  292. Linton, R. R.: Thromboembolic disease. Med. Clin. N. Amer. 30, 1068–1078 (1946).PubMedGoogle Scholar
  293. Litwins, J., J. J. Vorzimmer, L. N. Sussmann, N. Applezweig and A. D. Etesso: Sublingual administration of heparin. Proc. Soc. Exper. Biol. a. Med. 77, 325–326 (1951).Google Scholar
  294. Losse, H.: Zur Behandlung des frischen Herzinfarkts mit gerinnungshemmenden Substanzen. Dtsch. med. Wschr. 77, 1323–1325 (1952).PubMedGoogle Scholar
  295. Löffler, L.: Auf welchem Wege kommt die Zirkulation im künstlich embolisierten Lungenabschnitt wieder in Funktion ? Langenbecks Arch. u. Dtsch. Z. Chir. 266, 535–554 (1950).Google Scholar
  296. Löffler, L.: Lungenarteriögraphie. Leipzig: Thieme 1944.Google Scholar
  297. Loewe, L.: Anticoagulation therapy with heparin-Pitkin menstruum in thromboembolic disease. Amer. J. Med. 3, 447–467 (1947).PubMedGoogle Scholar
  298. Loewe, L.: and E. Hirsch: Heparin in the treatment of the thromboembolic Disease. J. Amer. Med. Assoc. 133, 1263–1268 (1947).Google Scholar
  299. Loewe, L.: and P. Rosenblatt: A new practical method for subcutaneous administration of heparin. Amer. J. Med. Sci. 208, 54–63 (1944).Google Scholar
  300. Loewe, L.: P. Rosenblatt: and N. Lederer: A new method of administering heparin. Proc. Soc. Exper. Biol. a. Med. 50, 53–55 (1942).Google Scholar
  301. Luke, J. C.: Evaluation of the deep veins following Previous thrombophlebitis. Arch. Surg. 61, 787–792 (1950).Google Scholar
  302. Macfarlane, R. G., and R. Biggs: Fibrinolysin: Its mechanism and significance. Blood 3, 1167–1187 (1948).PubMedGoogle Scholar
  303. Macht, D. J.: Experimental studies on heparin and its influence on Toxicity of Digitaloids, Congo Red, Cobra venom and other Drugs. Ann. Int. Med. 18, 772–791 (1943).Google Scholar
  304. Macht, D. J.: Influence of some drugs and of emotions on blood coagulation. Jama 148, 265–270 (1952).Google Scholar
  305. Macht, D. J.: Penicillin, Streptomycin Dicumarol and Blood-Coagulation. Thromboplastic properties of Penicillin. South. Med. J. 41, 720–727 (1948).PubMedGoogle Scholar
  306. Macht, D. J.: Special pharmacology of Digitoxins. I. Phytotoxic, Roentgenologic and colorimetric studies Arch, internat. Pharmacodynam. 81, 345–356 (1950).Google Scholar
  307. Macht, D. J.: Special pharmacology of Digitoxins. II Studies on cell respiration and blood coagulation. Arch, internat. Pharmacodynam. 85, 321–334 (1951).Google Scholar
  308. Macht, D. J.: Thromboplastic properties of Digitaloids and Mercurial Diuretics Employed in Cardiology. Arch, internat. Pharmacodynam. 72, 297–311 (1946).Google Scholar
  309. Macht, D. J.: Thromboplastic properties of Penicillin and Streptomycin. Science 105, 313–314 (1947).PubMedGoogle Scholar
  310. Macht, D. J.: and R. Farkas: Aureomycin and Blood Coagulation. Science 110, 305–306 (1949).PubMedGoogle Scholar
  311. Mangieri, C. N., R. Engelberg and L. O. Randall: Heparin-like activity of new anticoagulant Treburon. J. Pharmacol. 102, 156–164 (1951).Google Scholar
  312. Mann, F. D., and M. M. Hurn: Complex mechanisms of Quick prothrombin test and effect of dicumarol. Amer. J. Clin. Path. 20, 225–232 (1950).Google Scholar
  313. Mann, F. D., and M. M. Hurn: Effect of removal of liver on blood coagulation. Amer. J. Physiol. 164, 111 (1951).PubMedGoogle Scholar
  314. Mann, F. D., and M. M. Hurn: and T. B. Magath: Observations on conversion of prothrombin to thrombin. Proc. Soc. Exper. Biol. a. Med. 66, 33–35 (1947).Google Scholar
  315. Markees, S.: Über Vitamin E. Experimentelle Ergebnisse und therapeutische Erfahrungen. Internat. Z. Vitaminforsch. 22, 335–357 (1950).Google Scholar
  316. Marple, C.D., and J. S. Wright: Thromboembolic conditions and their treatment with anticoagulants. Springfield Ill.: Thomas 1950.Google Scholar
  317. Marshall, W.: Ambulatory therapy of thrombophlebitis with rutin and Vitamin C. Amer. J. Surg. 80, 52–56 (1950).PubMedGoogle Scholar
  318. Martini, G. A., u. H. Engelkamp: Capillarschäden durch Dysproteinämie und ihre Behandlung mit Rutin.—Beitrag zur Klärung der hämorrhagischen Diathese bei Leberkrankheiten. Dtsch. med. Wschr. 77, 833–837 (1952).PubMedGoogle Scholar
  319. Marx, R., U. H. Bayerle: Zum Problem der hämatologischen Diagnose der Thrombosegefährdung und der klinisch latenten Thrombose. Ärztl. Forsch. 4, I/72–80 (1950).Google Scholar
  320. Marx, R. U. A. Vath: Über experimentelle Untersuchungen mit einer synthetischen heparin-artigen Substanz (Polysaccharid-schwefelsäureester-Thrombocid) in Hinweis auf deren Verwendbarkeit als Anticoagulans und Antithromboticum. Ärztl. Forsch. 3, 131 (1949).Google Scholar
  321. Marx, R. U. A. Vath: u. H. Schmid: über den Einfluß von Anticoagulantien auf die Fibrinolyse i m menschlichen Serum. Ärztl. Forsch. 5, 1/192–1/200 (1951).Google Scholar
  322. Massie, E., H. J. Stillerman, C. S. Wright and V. Minnich: Effect of Administration of Digitalis on Coagulability of human blood. Proc. Soc. Clin. Res. 1, 44–45 (1944).Google Scholar
  323. Matis, P.: Verhütung dicumarolbedingter Gefäßschädigung durch Rutin, unter besonderer Berücksichtigung der Thromboembolieprophylaxe. Dtsch. med. Wschr. 74, 1576–1578 (1949).Google Scholar
  324. Matis, P.: Beitrag zur Gefäßwirkung von Heparinen und Heparinoiden. J. internat. Chir. (Belg.) 12, 281–283 (1952).Google Scholar
  325. Matis, P.: K. Bauer U. Ch. Rockstroh: Das Heparinoid Thrombocid in der Therapie und Prophylaxe thromboembolischer Zustände. N. Med. Welt 1950, 1520–1527.Google Scholar
  326. Matis, P.: H. Funfack u. Ch. Rockstroh: Untersuchungen über den Einfluß des Rutins auf die Blutgerinnung im Hinblick auf die Therapie und Prophylaxe mit Dicumarol bzw. Dicu-marolderivaten. Schweiz, med. Wschr. 80, 701–704 (1950).Google Scholar
  327. Matis, P.: u. R. Gross: Methodisches und Statistisches über die Retraktionszeit beim Gesunden und ihre Beziehungen zur Thrombocytenzahl und Gerinnungszeit. Med. Welt 1951, 492–496.Google Scholar
  328. Matis, P.: u. R. Gross: Über die tagesperiodischen Schwankungen der Thrombocyten und ihren Einfluß auf die Retraktilität des Blutkuchens. Schweiz, med. Wschr. 81, 1043–1045 (1951).Google Scholar
  329. Matis, P.: u. H. Hager: Zur Wirkung des Dicumarols auf die Permeabilität der Capillaren. Z. exper. Med. 118, 131–135 (1951).Google Scholar
  330. Maurer, K., U. E. Vincke: Die Synthese haparinwirksamer Verbindungen aus carboxylierter Cellulose. Chem. Ber. 80, 179–187 (1947).Google Scholar
  331. Mccann, J. C.: Thromboembolism. A comparison of the effect of early postoperative ambulation and Dicumarol on its incidence. New England J. med. 242, 203–207 (1950).Google Scholar
  332. Mccartney, J. S.: Postoperative pulmonary embolism. Surgery 17, 191–206 (1945).Google Scholar
  333. Mccleery, and J. A. Jarborough: A new tolerance Test as a guide to clinical heparin therapy Circulation 4, 394–401 (1951).Google Scholar
  334. Mccleery, R. S., C. P. Artz and H. D. Sivak: Practical application of the heparin-caronamide reaction to the potentiation of heparin in gelatin menstruum. Surgery 24, 348–354 (1948).PubMedGoogle Scholar
  335. Mcclure, R. D., C. R. Lam, J. Barron and R. R. Margulis: Clinical evaluation of two tests for incipient thrombosis. Prothrombin activity and fibrinogen B of Lyons. Ann. Surg. 130, 439–447 (1949).Google Scholar
  336. Mccormik, W. J.: Consideration sur l’etiologie de la thrombose coronarienne. Union méd. Canada 74, 1205–1212 (1945).Google Scholar
  337. Mcdevitt, E., R. D. Huebner and J. S. Wright: Ineffectiveness of heparin by sublingual administration. J. Amer. Med. Assoc. 148, 1123–1124 (1952).Google Scholar
  338. Mclachlin, J., and J. C. Paterson: Some basic observations on venous thrombosis and pulmonary embolism. Surgery etc. 93, 1–8 (1951).Google Scholar
  339. Mclachlin, J., R. Paul and J. C. Paterson: A critical evaluation of the antithrombin test for venous thrombosis. Surgery etc. 94, 297–301 (1952).Google Scholar
  340. Merz, W. R.: Die Behandlung der Thrombose und Lungenembolie mit Anticoagulantien. Basel u. New York: Karger 1950. Suppl. ad. Vol. 130 der Gynaecologia.Google Scholar
  341. Merz, W. R.: Thrombose und Lungenembolie. Basel: Benno Schwabe 1949. Helvet. chir. Acta (Helvet. med. Acta series B) Suppl. VI.Google Scholar
  342. Merz, W. R.: M. Etterich U. C. Scacchi: Die konservative Behandlung der Thrombose und Embolie in der Gynäkologie und Geburtshilfe, verglichen mit der antikoagulierenden Therapie. Schweiz, med. Wschr. 81, 565 (1951).Google Scholar
  343. Meunier, P., C. Mentzer et D. Molho: Sur l’activité antivitaminique K hemorrhagique d’une indanédione. C. r. Acad. Sci. (Paris) 224, 1166 (1947).Google Scholar
  344. Meyer, J. M.: Aureomycin-Clinical Toxicity; Prothrombin effect. J. Labor, a. Clin. Med. 36, 965 (1950).Google Scholar
  345. Meyer, O.: The ambulatorv treatment of phlebitis and thrombosis with compression bandages. Surgery 21, 843–850 (1947).PubMedGoogle Scholar
  346. Miller, R., W. P. Harvey and C. A. Finch: Antagonism of Dicumarol by vitamin K-Preparations. New England J. Med. 242, 211–215 (1950).Google Scholar
  347. Miller, R. D., R. A. Jordan, R. L. Parker and J. E. Edwards: Thromboembolism in acute and in healed Myocardial Infarction II Systemic and pulmonary arterial occlusion. Circulation 6, 7–15 (1952).PubMedGoogle Scholar
  348. Milstone, J. H.: Purification of thrombin. J. Gen. Physiol. 25, 679–687 (1942).PubMedGoogle Scholar
  349. Moeschlin, S., u. B. Koszewski: Komplikationen des Q-fever. Schweiz, med. Wschr. 80, 929–931 (1950).Google Scholar
  350. Moldavsky, L. F., W. B. Hasselbrook and G. D. Cateno: Studies in Mechanisms of Penicillin action: Penicillin Effect on Blood coagulation. Science 102, 38–40 (1945).PubMedGoogle Scholar
  351. Moolten, S. E., and L. Vroman: Adhesiveness of blood platelets in thromboembolism and hemorrhagic disorders. Amer. J. Clin. Path. 19, 701–709 und Vroman, J. M. S.: Amer. J. Clin. Path. 19, 814-826 (1949).Google Scholar
  352. Morgan, E. H., E. V. Allen and C. S. Maccarthy: Acute peripheral circulatory failure caused by acute venous thrombosis. Proc. Staff Meet. Mayo Clin. 23, 425–429 (1948).Google Scholar
  353. Morton, J. J., E. B. Mahoney and G. B. Mider: An evaluation of pulmonary embolism following intravascular venous thrombosis. Ann. Surg. 125, 590–603 (1947).Google Scholar
  354. Moss, N. H., R. L. Schäfer and Ch. K. Kirby: Anticoagulant effect of Dicumarol at-various prothrombin levels in Dogs. Proc. Soc. Exper. Biol. a. Med. 69, 143–145 (1948).Google Scholar
  355. Munt, J. D.: Activity of heparin in Pitkin’s menstruum. Lancet 259, 671–672 (1950).Google Scholar
  356. Murray, D. W. G.: Anticoagulants in venous thrombosis and the prevention of pulmonary embolism. Surgery etc. 84, 665–668 (1947).Google Scholar
  357. Murray, D. W. G.: Heparin in thrombosis and embolism. Brit. J. Surg. 27, 567–598 (1940).Google Scholar
  358. Murray, D. W. G.: and C. H. Best: Use of Heparin in thrombosis. Ann. Surg. 108, 163 (1938) und J. Amer. Med. Assoc. 110, 118 (1938).PubMedGoogle Scholar
  359. Naegeli, Th.: Entstehung, Verhütung und Behandlung der Thromboembolic mit besonderer Berücksichtigung der postoperativen Formen. Zbl. Chir. 74, 853–854 (1949) und Praxis 38, 454-460 (1949).Google Scholar
  360. Naegeli, Th.: u. P. Matis: Zur Therapie und Prophylaxe thromboemblischer Zustände mit gerinnungshemmenden Stoffen. N. Med. Welt 1950, 1139–1142.Google Scholar
  361. Naegeli, Th.: u. P. Matis: Tratamiento por la rutina en cirugia. Fol. Clin. Int. 2, 30–36 (1952).Google Scholar
  362. Nalefski, J. A., N. C. Gilbert and J. A. Sheedy: Viskosity studies on blood following the administration of anticoagulants. J. Labor, a. Clin. Med. 36, 970 (1950).Google Scholar
  363. Neumann, R.: Ursprungszentren und Entwicklungsformen der Bein-Thrombose. Virchows Arch. 301, 708–715 (1938).Google Scholar
  364. De Nicola, P.: Über die Entstehungsdauer der Blutgerinnungsfaktoren und ihre Verweildauer im Kreislauf. Klin. Wschr. 29, 278 (1951).Google Scholar
  365. Nonnenbruch, W., U. W. Szyska: Über einige neuartige Mittel (Euphyllin und andere Amine) zur Beschleunigung der Blutgerinnung. Dtsch. Arch. klin. Med. 134, 174–184 (1920).Google Scholar
  366. Obal, A.: Weiteres zum Hormon-Antagonismus Oestradiol-Progesteron. Die Medizinische 1952, 276–279 u. 885-888.Google Scholar
  367. Ochsner, A., and M. De Bakey: Postphlebitic sequelae. J. Amer. Med. Assoc. 139, 423–429 (1949).Google Scholar
  368. Ochsner, A., and M. De Bakey: Therapy of phlebothrombosis and thrombophlebitis. Arch. Surg. 40, 208–231 (1940).Google Scholar
  369. Ochsner, A., and M. De Bakey: Thrombophlebitis and Phlebothrombosis. South Surgeon 8, 269–290 (1939).Google Scholar
  370. Ochsner, A., and M. De Bakey: Thrombophlebitis, the role of vasospasm in the production of the clinical manifestations. J. Amer. Med. Assoc. 114, 117–124 (1940).Google Scholar
  371. Ochsner, A., and M. De Bakey: Venous thrombosis, a consideration of its cause, prevention treatment and sequelae. J. internat. Chir. 9, 310–311 (1949).Google Scholar
  372. Ochsner, A., and M. De Bakey: P. De Camp and J. M. Richmann: Postphlebitic syndrome. Treatment by conservative measures, Sympathectomy and other operative measures. Surgery 27, 161–182 (1950).PubMedGoogle Scholar
  373. Ochsner, A., J. H. Kay, P. T. De Camp, S. B. Hutton and G. A. Balla: Newer concepts of blood coagulation with particular reference to postoperative thrombosis. Ann. Surg. 131, 652–665 (1950).PubMedGoogle Scholar
  374. Olivier, Ch.: Pour le traitement anticoagulant des phlebitis récentes du membre inférieur. Presse méd. 58, 793–794 (1950).PubMedGoogle Scholar
  375. Olivier, Ch.: Les thromboses anciennes des veines iliaques primitives et externes; l’origine iliaque primitive gauche des phlébites dites du membre inférieur. Presse méd. 59, 1753 bis 1756 (1951).PubMedGoogle Scholar
  376. Olwin, J. H.: Control of Dicumarol therapy. Amer. J.Med. Sci. 217, 427–437 (1949).PubMedGoogle Scholar
  377. Olwin, J. H.: Diskussion zu J. S. Wright: Value of Prothrombin Determinations Transact. 1st Conf. on Blood clotting and allied Problems. New York Josiah Macy Jr. Foundation 1948.Google Scholar
  378. Olwin, J. J.: The significance of different methods for prothrombin estimation and their relative values. Surgery etc. 90, 423–429 (1950).Google Scholar
  379. Overman, R.: Proceedings 2nd Conf. on Blood clotting and allied Problems. Josiah Macy Foundation New York, Jan. 1949.Google Scholar
  380. Overman, R. J., M. A. Stahmann, W. R. Sullivan, C. F. Huebner, H. A. Campbell and K. P. Link: Studies on the sweet clover disease II. The effect of 3,3-methylene bis (4-hydroxycumarin) on prothrombin time of plasma of various animals. J. of Biol. Chem. 142, 941–955 (1942).Google Scholar
  381. Overman, R. S., C. W. Sorenson and J. S. Wright: Effectiveness of synthetic water soluble Vitamin K Preparation in Bishydroxycoumarin induced Hypopi othrombinemia. Jama 145, 393–399 (1951).Google Scholar
  382. Overman, R. S., and J. S. Wright: New blood clotting inhibitor. J. of Biol. Chem. 174, 759–760 (1948).Google Scholar
  383. Owren, P. A.: Fifth coagulation factor („factor V“) preparation and properties. Biochem. J. 43, 136–139 (1948).Google Scholar
  384. Owren, P. A.: Parahaemophilia; haemorrhagic diathesis due to absence of previously unknown clotting factor. Lancet 1, 446–448 (1947).PubMedGoogle Scholar
  385. Owren, P. A.: and K. Aas: Long term dicumaiol therapy, technic and results. III. Kongr. Europ. Haematolog. Ges. Rom 1951.Google Scholar
  386. Parkin, T. W., and F. W. Kvale: Neutralization of heparin with protamine (Salmine). J. Labor, a. Clin. Med. 32, 1396 (1947).Google Scholar
  387. Pelz: Penicillin as a blood coagulant—correspondence. Jama 134, 207 (1947), sowie 133, 800 (1947).Google Scholar
  388. Pere, S. A. N.: The effect of digitalis, strophanthin and novurit on blood coagulation. Acta med. scand. (Stockh.) 251 (1951).Google Scholar
  389. Perlow, S.: Phlegmasia cerulea dolens. J. Amer. Med. Assoc. 144, 1257–1258 (1950).Google Scholar
  390. Perret, H.: La phlebographies Helvet. chir. Acta 17, 269–276 (1950).Google Scholar
  391. Pilcher, R.: Postoperative Thrombosis and embolism. Mortality and morbidity. Lancet 2, 629–630 (1939).Google Scholar
  392. Piper, J. W.: Influence of synthetic polysaccharide sulfuric acid esters on thrombocytes in vivo and in vitro. Acta physiol. scand. 9, 28–33 (1945).Google Scholar
  393. Plungian, M. B., S. C. Münch, J. B. Wolffe: Effect of rutin on coagulation time of rat blood. J. Pharmacol, a. Exper. Ther. 93, 383–387 (1948).Google Scholar
  394. Pollack, A. A. and E. H. Wood: Venous pressure in saphenous vein at ankle in man During exercise and changes in Posture. J. Appl. Physiol. 1, 649–662 (1949).PubMedGoogle Scholar
  395. Popper, H., A. Dub In, F. Steigmann U. F. P. Hesser: Plasma-tocopherol levels in various pathologic conditions. J. Labor, a. Clin. Med. 34, 648–652 (1949).Google Scholar
  396. Powers, J. H.: Postoperative thiomboembolism; some remarks on influence of early ambulations. Amer. J. Med. 3, 224–230 (1947).PubMedGoogle Scholar
  397. Powers, J. H.: Prompt postoperative activity after Hernioplasty: Its influence on the incidence of complications and rate of recurrence. Arch. Surg. 59, 601–608 (1949).PubMedGoogle Scholar
  398. Powers, J. S., Jr.: Toxicity of dicumarol: Review of the literature and report of 2 cases. Ann. Int. Med. 32, 146–152 (1950).PubMedGoogle Scholar
  399. Pratt, G. H.: An early sign of femoral thrombosis. J. Amer. Med. Assoc. 140, 476–477 (1949).Google Scholar
  400. Pratt, G. H.: Classification and treatment of the varicose, postthrombotic, and arterial venous problems. Bull. New York Acad. Med. 26, 306–328 (1950).Google Scholar
  401. Pratt, G. H.: Control of pulmonary Embolism by inferior vena Cava ligation. J. Amer. Med. Assoc. 147, 126–127 (1951).Google Scholar
  402. Preston, F. W., W. R. O’connor, Ch. E. Thompson and E. N. Christensen: Clinical use of the anticoagulant Phenylindanedione-Report of 74 cases. Circulation 6, 515–519 (1952).PubMedGoogle Scholar
  403. Pulver, R., U. K. N. V. Kaulla: Über Resorption und biologische Inaktivierung des neuen Antithromboticums Tromexan. Schweiz, med. Wschr. 78, 956 (1948).Google Scholar
  404. Quattrin, N., e A. Camera: Azione di alcune sostanze sulla retrazione del coagulo. Gaz. med. ital. 111, 201–202 (1952).Google Scholar
  405. Quick, A. J.: Studies on enigma of hemostatic dysfunction of hemophilia. Amer. J. Med. Sci. 214, 272–280 (1947).PubMedGoogle Scholar
  406. Quick, A. J.: A new concept of venous thrombosis. Surg. etc. 91, 296–300 (1951).Google Scholar
  407. Quick, A. J.: Modern concepts of venous thrombosis. Practitioner 166, 313 (1951).Google Scholar
  408. Quick, A. J.: The value and significance of blood coagulation studies. Surg. etc. 95, 244–247 (1952).Google Scholar
  409. Quick, A. J.: J. N. Shanberge and M. Stefanini: Coagulation defect in thrombocytopenic purpura. J. Labor, a. Clin. Med. 34, 761–767 (1949).Google Scholar
  410. Quick, A. J.: J. N. Shanberge and M. Stefanini: The role of the platelets in the coagulation of blood. Amer. J. Med. Sci. 217, 198–205 (1949).PubMedGoogle Scholar
  411. Quick, A. J.: M. Stanley-Brown and F. W. Bancroft: A study of the coagulation defect in hemophilia and in jaundice. Amer. J. Med. Sci. 190, 501–511 (1935).Google Scholar
  412. Quick, A. J.: and M. Stefanini: Nature of action of labile factor in formation of thrombin. Amer. J. Physiol. 160, 572–575 (1950).PubMedGoogle Scholar
  413. Quick, A. J.: and M. Stefanini: The chemical state of the calcium l eacting in the coagulation of blood. J. Gen. Physiol. 32, 191–202 (1948).PubMedGoogle Scholar
  414. Rabinovich, J., and B. Pines: Effect of Heparin and Penicillin on experimentally produced thrombophlebitis. Arch. Surg. 58, 163–170 (1949).Google Scholar
  415. Ramsey, H., N. W. Pinschmidt and H. B. Haag: Effect of Digitalis upon Coagulation time of the blood. J. Pharmacol, a. Exper. Ther. 85, 159–169 (1945).Google Scholar
  416. Ratschow, M.: Die Vasoaffinität der Sexualhormone. Die Medizinische 1952, 608–613.Google Scholar
  417. Rehn, E.: Über die rationelle Thrombosebekämpfung zu einer emboliefreien Chirurgie. Dtsch. med. Wschr. 72, 18–14 (1947).PubMedGoogle Scholar
  418. Rehn, E.: u. Th. Halse: 5 Jahre postoperative Dicumarol-Prophylaxe, eine statistische Bilanz. Dtsch. med. Wschr. 74, 1552–1556 (1949).Google Scholar
  419. Rehn, E.: u. K. N. v. Kaulla: Zur klinischen Lösung des Thromboembolieproblems. Vorträge aus der praktischen Chirurgie 32. Heft. Stuttgart: Enke 1947.Google Scholar
  420. Reifferscheid, M., U. P. Matis: Das Vitamin E in der Behandlung vonDurchblutungs-schäden, Dupuytren-Kontraktur und Thrombosen. Med. Welt 1951, 1168–1172.Google Scholar
  421. Richardson, J. A., F. C. Hays and R. P. Walton: Effect of various agents on blood coagulation time in Dogs. J. Pharmacol, a. Exper. Ther. 85, 146–150 (1941).Google Scholar
  422. Richter, I. H., R. F. Del Nunzio and S. L. Swiller: An Evaluation of the Dicumarol therapy in 300 Cases of myocardial Infarction. New York Stata J. of Med. 52, 1301–1303 (1952).Google Scholar
  423. Richter, K., U. W. Albrich: Über den Einfluß der weiblichen Sexualhormone auf die Permeabilität. V. österr. Ärztetagung. Tagungsbericht, S. 535–541. Wien: Springer 1951.Google Scholar
  424. Rieben, W. K.: Beiträge zur Kenntnis der Blutgerinnung. Basel: Schwabe & Co. 1947.Google Scholar
  425. Rieben, W. K.: Beobachtungen mit einer neuen Prothrombinbestimmungsmethode. Helvet. med. Acta 13, 295–303 (1946).PubMedGoogle Scholar
  426. Riecke, Gr.: Kann der Grad der Mikrohämaturie als Testmethode bei der Behandlung mit Anticoagulantien verwendet werden? Die Medizinische 1952, 178–179.Google Scholar
  427. Ritter, A.: Die Aetiologie der postoperativen Venenthrombose als Ursache der postoperativen Thromboembolie nach neueren Untersuchungsergebnissen. Rapport présenté à la Société Internationale de Chirurgie, Varsovie, Juillet 1939. Bruxelles Imprimeric Médicale et Scientifique (1929).Google Scholar
  428. Ritter, A.: Endothel und Thrombenbildung. Dtsch. med. Wschr. 54, 1963–65 (1928).Google Scholar
  429. Robertson, H. E.: A clinical study of pulmonary embolism. Amer. J. Surg. 41, 3–21 (1938).Google Scholar
  430. Robertson, H. E.: Pulmonary embolism, following surgical operation. Amer. J. Surg. 26, 15–18 (1934).Google Scholar
  431. Robertson, S. J., S. Wolf U. H. G. Wolff: Blood „sludge“ phenomenon in human subjects. Amer. J. Med. Sci. 219, 534–537 (1950).PubMedGoogle Scholar
  432. Roe, B. B., and J. C. Goldthwait: Pulmonary Embolism; A statistical study of post-mortem material at Massachusetts General Hospital. New England J. Med. 241, 679–686 (1949).Google Scholar
  433. Rogers, J. F., R. J. Barret and C. R. Lam: The effect of moderate degrees of Dicumarol induced Hypoprothrombinemia on experimental intravascular Thrombosis. Surgery etc. 89, 339–344 (1949).Google Scholar
  434. Ronhier: A propos du lever précoce des opérés. Mém. Acad. Chir. 76, 101–103 (1950).Google Scholar
  435. Rose, C.L., P.N. Harris U. K. K. Chen: Toxicity of 3,3-methylene-bis (4-hydroxycou-marin). Proc. Soc. Exper. Biol. a. Med. 50, 228–232 (1942).Google Scholar
  436. Rosenthal, R. L.: Blood coagulation in Leucemia and Polycythemia; Value of the Heparin Clotting Time and Clot Retraction Rate. J. Labor, a. Clin. Med. 34, 1321–1335 (1949).Google Scholar
  437. Rössle, R.: Über die Bedeutung und Entstehung der Wadenvenenthrombose. Virchows Arch. 300, 180–189 (1947).Google Scholar
  438. Runge, H.: Betrachtungen zur Pathogenese und Klinik der Thromboembolie. Dtsch. med. Wschr. 77, 1079–1081 (1952).PubMedGoogle Scholar
  439. Runge, H.: u. J. Hartert: Bericht über 1/2 Jahre einer gezielten Prophylaxe der Thromboembolie. Klin. Wschr. 30, 385–390 (1952).PubMedGoogle Scholar
  440. Runge, H.: u. J. Hartert: Untersuchungen mit Depot-Liquemin. Geburtsh. u. Frauenheilk. 12, 506–510 (1952).Google Scholar
  441. Rutledge, D. J.: Studies on venous pressure. Diss. Graduate School of the University of Minnesota 1941.Google Scholar
  442. Sachs, J. J., and R. R. Henderson: Use of bishydroxycoumarin (Dicumarol) in the presence of impaired renal function. J. Amer. Med. Assoc. 148, 839–841 (1952).Google Scholar
  443. Salvatore, C. A.: Capillary fragility and menstruation. Surg. etc. 95, 13–16 (1952).Google Scholar
  444. Scheele, J. u. P. Matis: Zur Frage der Venostasinwirkung unter Berücksichtigung der Therapie und Prophylaxe der thromboembolischen Krankheit. Die Medizinische 1952, 693–696.Google Scholar
  445. Schmid, H., u. R. Marx: Zur Frage der Capillarschädigung unter Dicumaroltherapie und deren Beeinflussung durch Rutin. Med. Klin. 46, 812–814 (1951).Google Scholar
  446. Schoen, R., W. Tischendorf U. W. Wepler: Schäden durch Dicumarol. Münch. med. Wschr. 93, 21–28 (1951).PubMedGoogle Scholar
  447. Schreck, W.: Über die Anwendung von Depot-Thrombocid bei Thrombosen und Embolien. Dtsch. med. Wschr. 76, 1560–1562 (1951).PubMedGoogle Scholar
  448. Schreck, W.: Über die Behandlung von Thrombosen und Embolien mit den Anticoagulantien Dicuman und Thrombocid. Münch. med. Wschr. 93, 1170–1175 (1951).PubMedGoogle Scholar
  449. Schultz, E. W., J. K. Nicholes U. J. H. Schäfer: Studies on blood fibrin. Its quantitative determination, normal fibrin values and factors which influence the quantity of blood fibrin. Amer. J. Path. 1, 101–115 (1925).PubMedGoogle Scholar
  450. Schultze, H. E.: Theoretische und experimentelle Grundlagen der Prothrombinbestimmung unter Berücksichtigung des Prothrombin-Accelerators. Arch, exper. Path. u. Pharmokol. 207, 173–202 (1949).Google Scholar
  451. Schwiegk, H.: Der Lungenentlastungsreflex. Pflügers Arch. 236, 206–219 (1935).Google Scholar
  452. Scott, W. J.: Postphlebitic and varicose venous stasis—clinical results of treatment by pulsatile air pressure principle. J. Amer. Med. Assoc. 147, 1195–1201 (1951).Google Scholar
  453. Seegers, W. H., R. J. McClaughry and J. L. Fahey: Some properties of purified prothrombin and its activation with Sodium citrate. Blood, 5, 421–433 (1950).PubMedGoogle Scholar
  454. Seifter, J., and A. J. Begany: Studies on the action of a synthetic heparinoid. Amer. J. Med. Sci. 216, 234–236 (1948).PubMedGoogle Scholar
  455. Shapiro, J., and M. Weiner: Coagulation, Thrombosis and Dicumarol with an appendix on relative laboratory Procedures. New York, Brooklyn Medical Press 1949.Google Scholar
  456. Shapiro, S.: The hypoprothrombinemia-inducing activity of Links Compound 63 (metha-pyranorin). Acta haemat. 6, 129 (1951).PubMedGoogle Scholar
  457. Shea, C. P. Jr., and R. L. Robertson: Late sequelae of inferior vena cava Ligation. Surgery etc. 93, 153–158 (1951).Google Scholar
  458. Short, D. S.: A survey of pulmonary embolism in a general hospital. Brit. Med. J. 1952, 790–796.Google Scholar
  459. Sigg, K.: Die Schaumgummi-Kompression der Phlebitis sowie der phlebitischen und varicösen Komplikationen. Die Medizinische 1952, 910–915.Google Scholar
  460. Sigg, K.: Ulcus cruris, Varizen und varicose Thrombophlebitis. Schweiz, med. Wschr. 74. 700 (1944).Google Scholar
  461. Sirak, H. D., R. S. Mc Cleery and C. P. Artz: The effect of caronamide with heparin on the coagulation of human blood, a preliminary report. Surgery 24, 811–818 (1948).PubMedGoogle Scholar
  462. Smith, R. W., R. R. Margulis, M. J. Brennan and R. W. Monto: The influence of Acth and Cortisone on certain factors of blood coagulation. Science 112, 295–297 (1950).PubMedGoogle Scholar
  463. Smith, W. B., L. Rosenfeld and G. Y. Shinowara: The coagulation factors in plasma of cancer patients. Cancer Res. 11, 281 (1951).Google Scholar
  464. Sörenson, C. W., J. Seifter and J. S. Wright: A new synthetic anticoagulant (Heparinoid) Preliminary Report of its action in Humans. Bull. New York Acad. Med. 25, 448 (1949).Google Scholar
  465. Sörenson, C. W., and J. S. Wright: A Synthetic anticoagulant: A polysulfuric acid ester of Polyanhy-dromannuronic Acid (Paritol). Experience with its use in man. Circulation 2, 658–667 (1950).PubMedGoogle Scholar
  466. Soulier, J. P., et J. Gueguen,: Action hypoprothrombinémiante (anti-K) de la phéyl-indanedione studi: expérimentalement chez le lapin. Son application chez l’homme. Compl. rend. Soc. de Biol. 141, 1007 (1947).Google Scholar
  467. Spang, K., C. Keller U. H. Hartert: Digitalis und Blutgerinnung. Dtsch. med. Wschr. 77, 448–453 (1952).PubMedGoogle Scholar
  468. Spitzer, J. M., M. Rosenthal, M. Weiner U. Sh. Shapiro: Relation of pulmonary embolism to peripheral thrombosis. Arch. Int. Med. 84, 440–444 (1919).Google Scholar
  469. Spohn, K.: Die tödlichen Lungenembolien an den Heidelberger Kliniken (Untersuchung von 377 Fällen der letzten 20 Jahre). Langenbecks Arch. u. Dtsch. Z. Chir. 269.518–542(1951).Google Scholar
  470. Spohn, K.: u. G. Peschel: Kritische Betrachtungen zur percutanen Beeinflußbarkeit der Blutgerinnung durch Hirudoid. Chirurg 22, 481–483 (1951).PubMedGoogle Scholar
  471. Staehler, W.: Die Embolieprophylaxe in der Urologie, insbesondere bei operativen Eingriffen an der Prostata. Fortschr. Med. 69, 39–41 (1951).Google Scholar
  472. Stefanini, M.: Conversion factors and accelerators in the formation of Thrombin. Blood, 6, 84–93 (1951).PubMedGoogle Scholar
  473. Stefanini, M.: Studies on role of calcium in coagulation of blood. Acta med. scand. 136, 250–266 (1950).PubMedGoogle Scholar
  474. Struppler, A.: Ein weiterer Beitrag zur percutanen Beeinflussung der Blutgerinnung. Med. Welt. 1951, 856–858.Google Scholar
  475. Stutz, H.: Klinische Erprobung eines neuen konzentrierten wässrigen Heparinpräparates mit intramuskulärer Anwendung.Google Scholar
  476. Sulamaa, M., u. A. Pentti: On thromboembolic diagnosis in praxis and on the need of anticoagulant prophylaxis. Acta chir. scand. 98, 130–141 (1949).Google Scholar
  477. Szilagyi, D. W., and J. F. Alsop: Early and late sequelae of therapeutic vein ligation for thrombosis of the veins of the lower limbs. Arch. Surg. 59, 633–666 (1949).PubMedGoogle Scholar
  478. De Takats, G.: Heparin tolerance. A test of clotting mechanism. Surgery etc. 77, 31–39 (1943).Google Scholar
  479. DE Takats, G.: Thromboembolism. J. internat. Chir. 8, 903 (1947).Google Scholar
  480. De Takats, G.: and G. W. Graupner: Division of the popliteal vein in deep venous insufficiency of the lower extremities. Surgery, 29, 342–354 (1951).PubMedGoogle Scholar
  481. De Takats, G.: R.A. Trump and N. C. Gilbert: Effect of Digitalis on the clotting mechanism. Jama 125, 840–845 (1944).Google Scholar
  482. Tanaka, H.: Über den Einfluß des Strophanthins auf die Gerinnbarkeit des Blutes. Akayama-Igokkai-Zasshi 40, 1817 (1928).Google Scholar
  483. Tannenberg, J., U. B. Fischer-Wasels: Die lokalen Kreislaufstörungen. Handb. d. norm, u. path. Physiologie von Bethe—v. Bergmann—Embden—Ettinger. Bd. 7, II, 1726–1793. Berlin: Springer (1927).Google Scholar
  484. Thébaut, B. R., and C. S. Ward: Ligation of the inferior vena cava in thromboembolism.-Report of 36 cases. Surgery etc. 84, 385–401 (1947).Google Scholar
  485. Thomaschek, G.: Klinische Kritik des synthetischen Heparins Thrombocid in der Geburtshilfe und Frauenheilkunde. Geburtsh. u. Frauenheilk. 11, 1077–1089.Google Scholar
  486. Thomaschek, G.: Über die Zunahme der postoperativen Thrombo-Embolie und deren Behandlung mit Anticoagulantien. Geburtsh. u. Frauenheilk. 11, 1067–1077 (1952).Google Scholar
  487. Trémolières, T. et P. Veran: Syndrome d’oblitération artérielle du membre inférieur droit apparu au cours d’une phlébite superficielle et profonde avec embolies pulmonaires. Effet thérapeutique de l’acetylcholine. Bull. méd. Par. 43, 1101–1111 (1929).Google Scholar
  488. Trethewi, E. R., D. Carman and A. J. Day: The value of fibrinogen-B Test in intravascular Thrombosis in surgical subjects. Brit. J. Surg. 38, 30–37 (1950).Google Scholar
  489. Ungar, G., and S. Mist: Observations on release of serum fibrinolysin by specific antigen, pentone and certain polysaccharides. J. exper. Med. 90, 39–51 (1949).Google Scholar
  490. Veal, J. S., and H. H. Hussey: Surgery of deep venous thrombosis of lower extremity. Surgery 17, 218–231 (1945).Google Scholar
  491. Verstraete, M., and J. Vandenbroncke: Action of Acth and cortisone on blood coagulation. 3. Kongr. Europ, Hämatol. Ges. Rom 1951.Google Scholar
  492. Vorhees, A., and E. Pulaski: The fibrinogen B test and intravascular Thrombosis. J. Labor, a. Clin. Med. 34, 1352–1355 (1949).Google Scholar
  493. Waisbren, B. A., and D. Glick: Effect of Aureomycin on Heparin concentration and clotting time of human blood. Proc. Soc. Exper. Biol. a. Med. 75, 476–477 (1950).Google Scholar
  494. Walker, J.: The efficacy of heparin administration by intravenous intramuscular and subcutaneous routes and a study of the effects of 5 bacteriostatic agents on heparin action. Surgery 17, 54–60 (1945).Google Scholar
  495. Walker, J.: Treatment of postphlebitic leg and application of venous pressure measurements. Brit. Med. J. 1950, 1307–1310.Google Scholar
  496. Walker, J.: and J. E. Rhoads: Effect of Dicumarol on Insusceptibility to action of heparin. Surgery 15, 859–865 (1944).Google Scholar
  497. Ware, A. G., M. M. Guest and W. H. Seegers: A factor in plasma which accelerates the activation of prothrombin. J. Biol. Chem. 169, 231–232 (1947).PubMedGoogle Scholar
  498. Ware, A. G., M. M. Guest and W. H. Seegers: Plasma accelerator factor and purified prothrombin activation. Science 106, 41–42 (1947).PubMedGoogle Scholar
  499. Ware, A. G., and W. H. Seegers: Two stage procedure for the quantitative determination of prothrombin concentration. Amer. J. Clin. Path. 19, 471–482 (1949).Google Scholar
  500. Warner, E. D., K. M. Brinkhous and H. P. Smith: Prothrombin fluctuations under experimental conditions. Amer. J. Physiol. 114, 667–675 (1936).Google Scholar
  501. Weger, P.: Wirkung des Strophantins auf die Formelemente des Blutes, speziell auf die Thrombocyten und Leukocyten. Scand. arch. Physiol. 56, 291 (1929).Google Scholar
  502. Weiner, M., J. Axelrod, S. Shapiro and B. R. Brodie: Fate of Dicumarol in man. Federat. Proc. 8, 345–346 (1945).Google Scholar
  503. Weiner, M., K. Feltmacher and S. Shapiro: Effect of Penicillin upon coagulability of Blood. Exper. Med. a. Surg. 6, 181–188 (1948).Google Scholar
  504. Weiss, A.-G., et L. Hollender: Accident Mortel provoqué par de faibles doses de Dicoumarol. Presse Méd. 59, 584 (1951).PubMedGoogle Scholar
  505. Welch, C. E., and H. Faxon: Thrombophlebitis and pulmonary embolism. J. Amer. Med. Assoc. 117, 1502–1508 (1941).Google Scholar
  506. Wellman, W. E., and E. V. Allen: The variable effects of identical amounts of Dicumarol on the prothrombin values of different persons. Proc. Staff Meet. Mayo Clin. 26, 257–260 (1951).PubMedGoogle Scholar
  507. Wenzl, M., U. R. Kühlmeyer: Ein statistisch-klinischer Beitrag zum Problem der Thrombo-emboliegefährdung. Langenbecks Arch. u. Dtsch. Z. Chir. 269, 46–60 (1951).Google Scholar
  508. Werch, S. C.: Reduction of Coagulation time of Rabbits blood by Digitalis. Quart. Bull. Northw. Univ. Med. 17, 50–51 (1943).Google Scholar
  509. Wigginton, R. C, W. H. Parsons and W. K. Purks: Thrombosis and Embolism: The 5-year Experience of a small general Hospital. Ann. Surg. 129, 784–796 (1949).Google Scholar
  510. Wilson, H.: Surgery for the prevention of pulmonary embolism. Amer. J. Surgery 78, 421 bis 430 (1949).Google Scholar
  511. Wimhöfer, H., U. J. Hartert: Ergebnisse systematischer Vorbeugung und Behandlung der Thromboembolie mit Anticoagulantien. Geburtsh. u. Frauenheilk. 11, 1059–1067. (1951). Ergebnisse der Chirurgie, Bd. 38. 2Google Scholar
  512. Wollheim, E.: Klinik embolischer Organerkrankungen. Regensburger Jb. ärztl. Fortbildg. 2, 300–310 (1952).Google Scholar
  513. Wollheim, E.: Untersuchungen zur Hämodynamik unter Digitalis und Strophantin. Dtsch. med. Wschr. 75, 482–486 (1950).PubMedGoogle Scholar
  514. Wollheim, E.: Herzinfarkt und Angina Pectoris. Dtsch. med. Wschr. 57, 617–619 (1931).Google Scholar
  515. Wollheim, E.: Die Blutreservoire des Menschen. Klin. Wschr. 12, 12–16 (1933).Google Scholar
  516. Wood, L. A., F. E. Horan, E. Sheppard and J. S. Wright: Zeta potential measurements as a tool for studying certain aspects of blood coagulation. Transact. 3rd Conf. on Blood clotting and allied Problems. Josiah Macy, Jr. Foundation 1950.Google Scholar
  517. Woolridge, W. E., and M. Hoffmann: Unaltered Prothrombin Times in Patients treated with oral Glucomycin. Antibiotics 1, 249–252 (1951).Google Scholar
  518. Wright, H. P.: Changes in adhesiveness of blood platelets following parturition and surgical operations. J. Path. a. Bact. 54, 461–468 (1942).Google Scholar
  519. Wollheim, E.: The Adhesiveness of blood platelets in rabbits, treated with Dicumarol. J. Path. a. Bact. 57, 382–385 (1945).Google Scholar
  520. Wright, J. S.: Dauerbehandlung mit Anticoagulantien. Die Medizinische 1952, 613–617.Google Scholar
  521. Wright, J. S.: The Pathogenesis and Treatment of Thrombosis (The George E. Brown Memorial Lecture). Circulation 5, 161–188 (1952).PubMedGoogle Scholar
  522. Wright, J. S.: Vascular Diseases in clinical Practice 2nd Ed. The Year Book publishers Inc. Chicago 1952.Google Scholar
  523. Wright, J. S.: G. E. Burke and L. A. Scarone: Experimentelle und klinische Erfahrungen mit Trome-xan (3,3’-(4-oxycumarinyl)-essigsauresethylester. Med. Welt 1951, 1469–1471.Google Scholar
  524. Wright, J. S.: and W. T. Foley: Use of anticoagulants in the treatment of heart disease with special reference to coronary thrombosis rheumatic heart disease with thromboembolic complications following major surgery. A four year survery 3504 cases. Surgery etc. 88, 486 (1949).Google Scholar
  525. Wright, L. T., and M. Rothman: Deaths from dicumarol. Arch. Surg. 62, 23–28 (1951).Google Scholar
  526. Wylie, E. J., R. E. Gardner, R. Johansen and H. J. Mccorkle: An experimental study of Regional Heparinization. Surgery 28, 29–36 (1950).PubMedGoogle Scholar
  527. Wynn, A., J. F. Goodwin U. A. Birbeck: Prolonged anticoagulant therapy with Heparin. Brit. Med. J. 1952, 893–896.Google Scholar
  528. Zehnder, M.: Flüssiges Blut durch Thrombolyse in doppelt unterbundenen Gefäßstrecken. Helvet. Chir. Acta 14, 162–180 (1947).PubMedGoogle Scholar
  529. Zetler, G.: Über die Beziehung zwischen lokaler Kältschädigung, Blutgerinnung und Histamin, ihre Beeinflussung durch Antihistaminica. Arch, exper. Path. u. Pharmakol. 213, 18 (1951).Google Scholar
  530. Zierler, K. L. D. Grob U. J. L. Lilienthal, Jr: On the antithrombic and antiproteolytic activity of alpha tocopherol phosphate. Amer. J. Physiol. 153, 127–132 (1948).PubMedGoogle Scholar
  531. Zilliacus, H.: Die thromboembolische Krankheit. Med. Welt 20, 343–346 (1951).PubMedGoogle Scholar
  532. Zilliacus, H.: On the specific treatment of thrombosis and pulmonary embolism with anticoagulantia. With particular reference to the postthrombotic sequelae. The result of five years treatment of thrombosis and pulmonary embolism at a series of Swedish Hospitals during the years 1940-45. Acta med. scand. Suppl. 171 (1946).Google Scholar
  533. Zucker, H. D.: Clinical experiences with dicumarol; report of 18 cases. J. Amer. Med. Assoc, 124, 217–220 (1944).Google Scholar
  534. Zucker, H. D.: Platelet thrombosis in human hemostasia. A histiologic study of skin wounds in normal and purpuric individuals. Blood 4, 631–645 (1949).PubMedGoogle Scholar
  535. Zucker. M. B.: Platelet agglutination and vasoconstricion as factors in spontaneous hemo-stasis in normal, thrombocytopenic heparinized and hypoprothrombinemic rats. Amer. J. Physiol. 148, 275–288 (1947).PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1953

Authors and Affiliations

  • Th. Naegeli
  • P. Matis

There are no affiliations available

Personalised recommendations